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 Abstract 
Background 
Middle ear infections (otitis media) are a significant burden on children‟s health. 
They are one of the more common childhood ailments and are responsible for 
about a third of children‟s general practitioner visits. Three bacteria of the 
nasopharynx have been well documented as true pathogens of otitis media. These 
are Haemophilus influenzae, Streptococcus pneumoniae, and Moraxella 
catarrhalis. A newer bacterium, Alloiococcus otitidis, which is more difficult to 
culture than the initial three pathogens, was discovered in 1989 by Faden & Dryja.  
The pathogenicity of A. otitidis in otitis media is controversial, as is the 
association of two other bacteria, Turicella otitidis and Corynebacterium auris. 
These three bacteria are regarded as commensals of the outer ear canal, and how 
they move into the middle ear is subject to much debate. My hypothesis is that 
during a primary middle ear infection, commensal bacteria of the external ear 
canal may be able to move through the inflamed tympanic membrane and into the 
middle ear where they act as opportunistic pathogens. This may create a more 
persistent bacterial infection, with greater resistance to antibiotic therapies.  
Methods 
DNA was extracted directly from swabs of the outer ear canal and nasopharynx of 
children with otitis media and otitis-free controls, and from the middle ear 
exudates of the otitis media study group. This DNA was then amplified using 
primers specific for each of the organisms of interest. The presence of a specific 
PCR product, confirmed by DNA sequencing, indicated a positive result. 
Swabs from each of the sites of interest were also grown on 10% Columbia blood 
agar, 10% Columbia chocolate agar and in BHI broth supplemented with foetal 
calf serum. These results gave further information on bacterial presence in New 
Zealand children beyond the six studied.  
Sau-PCR microbial community profiling was used to demonstrate the diversity of 
species present in the polymicrobial samples. DNA was restriction digested and 
the resulting banding patterns were compared between study sites, and study 
groups. 
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Results and Conclusions 
Moraxella species colonised the outer ear canal of control participants more 
regularly than the outer ear canal of otitis media patients (58% vs. 33%). This 
difference was found to be statistically significant (p= 0.0023). Differences 
between the colonisation of the outer ear canal and nasopharyngeal body sites 
were found at a statistically significant level in control participants with A. otitidis 
(p=0.0433), C. auris (p=0.0000), T. otitidis (p=0.0050) and Moraxella spp. 
(p=0.0005). Of the same body sites in otitis media patients, only the colonisation 
of C. auris (p=0.0002) and T. otitidis (p=0.0004) were found to be statistically 
significant. This shows that four of the six studied bacteria colonise both 
anatomical sites in otitis media patients in a similar manner (without statistical 
significance), as opposed to only two in the control participants. 
Of the six bacterial species analysed using non-culture techniques, S. pneumoniae, 
H. influenzae and C. auris failed to be cultured. This may show that storage prior 
to analysis made samples less suitable for culture based research. A number of 
other species were cultured, with subsequent sequencing identifying them. This 
included species thought to be associated with a decreased risk of developing 
otitis media, found in both of the control participant nasopharynxes that were 
studied, and in only one nasopharynx from the otitis media group. A. otitidis was 
cultured regularly in outer ear samples, and one middle ear effusion. 
Sau-PCR microbial profiling was an effective but crude indication of microbial 
diversity. Otitis media patient nasopharyngeal profiles resembled each other, with 
resemblance extending to the middle ear effusion profile. Control participant 
banding patterns within sites were similar, but this resemblance did not extend to 
the otitis media group profiles. Comparisons between the banding patterns from 
known bacterial species to those of unknown polymicrobial species were useful if 
the identifying species had a unique banding pattern, as with A. otitidis. Sau-PCR 
therefore proved useful in analysing the complexities that are polymicrobial 
samples, however identifications of these species by cloning proved unsuccessful. 
Further research using all the techniques above with increased numbers of 
participants is necessary to substantiate results of this study. Information on 
antibiotic resistance, viral presence, and biofilm status could prove useful 
information in helping treat infection. 
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1 Chapter 1: Introduction and 
Literature Review 
1.1  Introduction: Middle ear disease 
Middle ear infection (Otitis media (OM)) is the most common childhood illness 
throughout the world and represents the leading reason for prescription of 
antibiotic agents (O'Brien et al. 2009). Unfortunately, antimicrobial therapy is 
sometimes ineffective against these polymicrobial infections, leading to the 
necessity for surgical intervention (Brogden & Guthmiller 2002). Tympanostomy-
tube insertions, a procedure specifically for the treatment of OM, are at present the 
most frequently performed surgical procedure on children in the United States 
(O'Brien et al. 2009).  
Acute otitis media (AOM) is the initial form of infection. Symptoms include pain, 
caused by an inflamed tympanic membrane (ear drum), and fluid in the middle ear 
(Barnett 2007). AOM can be referred to as recurrent acute otitis media (rAOM) 
after 3 or 4 cases over a 6 month or 12 month period, respectively. Chronic forms 
of infection include otitis media with effusion (OME), in which a middle ear 
effusion (MEE) fills the middle ear cavity. This MEE is a fluidic substance that 
can decrease hearing capabilities, but is often painless and if left untreated, can 
lead to mastoiditis (inflammation of the mastoid bone) or even deafness 
(Hoberman et al. 2011).  
The nasopharynx (NP), of the upper respiratory system, is thought to play a role in 
episodes of OM. Also involved are two areas of the auricular system, the middle 
ear, and the outer ear canal (OE) (see Figure 1.1). Extensive bacterial colonisation 
is proven in the NP (Brook 2011) and the OE (De Baere et al. 2009). There is 
little evidence of bacterial colonisation of the healthy middle ear (prior to an 
episode of OM), therefore it is currently perceived to be sterile (Murphy et al. 
2009). 
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Figure 1.1 Schematic of the auricular system, including the nasopharynx. 
Key areas to note are the middle ear, the outer ear canal, and the 
nasopharynx (ME220: Introduction to Sensors  2008). 
Three commensal bacteria of the NP (Figure 1.1) are known and proven 
pathogens of OM. These are Streptococcus pneumoniae, non-typable 
Haemophilus influenzae, and Moraxella catarrhalis (De Baere et al. 2009). These 
asymptomatically frequent the NP of many children. Pathogenicity is selected for 
during times of immune impairment, such as those caused by contraction of a 
viral agent. An episode of OM is thought to be provoked by the impaired 
functioning of the immune response in the Eustachian tubes, which would allow 
bacteria from the NP to ascend into the middle ear cavity (Figure 1.1). 
Three other opportunistic bacteria that have a potential role in OM are 
Alloiococcus otitidis, Corynebacterium auris, and Turicella otitidis. These are all 
commensal bacteria of the OE with unknown and/or controversial roles in OM 
(Holzmann et al. 2002; Tano et al. 2008). Potentially, an initial episode of OM 
may lead to the weakening of the ear drum, allowing bacteria to invade the middle 
ear cavity from the OE. No research into the subject has currently been completed 
to neither confirm nor deny this possibility.  
If this were to occur, the potential for exacerbation of infection by addition of 
further biofilm contributors or antibiotic resistant species could lead to more 
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chronic forms of infection. All six of the aforementioned bacteria have been found 
in the MEE of OM patients, leading to their association with the disease.  
1.2 Common flora of the auricular system 
The nasopharynx, oropharynx, oral cavity, and auricular system represent a 
number of ecological niches. This allows for a vast array of both eukaryotic, but 
predominantly prokaryotic colonisation. Greater than 800 bacteria are attributed to 
these areas, but of this array of species, only a small subset are thought to cause 
clinical infections (Bogaert et al. 2011). 
Polymerase chain reaction (PCR) and DNA based analysis have made the 
detection of bacterial or viral presence possible without initial culture. Viable 
organisms are often not culturable (Morris et al. 2009). This could be due to 
dormancy (common in a biofilm environment), death from previous antibiotic 
treatment, or because specific nutritional requirements are not present in 
conventional microbiological media. However, using these DNA based methods, 
bacterial presence can be registered without initial culture. This has allowed for a 
more complete picture of the microbiota associated with the NP and auricular 
system. 
The Human Microbiome Project (HMP) involves a number of organisations and 
institutions which collectively are attempting to isolate and sequence all the 
bacteria associated with the human body (NIH Human Microbiome Project  2011). 
The HMP catalogue holds current data describing the different bacteria isolated, 
and has the option of filtering by body site.  
As of the 23
rd
 of January 2012, 3 bacteria of the nose and 388 of the oral cavity 
had been identified, and were in the process of being analysed by the HMP. 
Although the species present in the OE and NP are yet to be analysed extensively 
by this organisation, papers that look into the microbiome of these areas have 
been published. Both culture and non-culture based techniques have been used to 
analyse these areas. 
 Outer ear bacteria 1.2.1
Extensive diversity of bacterial species has been noted in the OE. Evidence of this 
is shown in a study by Frank et al (2003) who cloned and sequenced the 16S gene 
of OE organisms from 24 individuals, avoiding culture bias by extracting DNA 
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directly from samples (see Table 1.1) (Frank et al. 2003). Eukaryotes, such as the 
fungus Tilletiaria anomala, and the mite, Trhypochthonius tectorum were present 
amongst the predominantly prokaryotic microbiota.  
Using these culture-independent techniques, A. otitidis (Table 1.1 refers to this 
species as A. otitis) was seen to be the most prevalent bacteria of this area (Frank 
et al. 2003). A. otitidis is slow growing and requires a particular media of 5% 
blood agar, therefore complicating identification by culture (Faden & Dryja 1989). 
T. otitidis (in Table 1.1 referred to as C. otitidis, the name was later revised) was 
the next most prevalent species, with C. auris a distant fourth. These three 
organisms are of great importance to this research, and will be discussed in further 
detail in coming sections. 
Stroman et al (2001) also looked at the microbiology of the OE, but used culture 
techniques instead (Stroman et al. 2001). Of 310 canal samples, 7 were positive 
for C. auris, 36 for T. otitidis and 20 for A. otitidis. In 314 cerumen samples, 8 
were positive for C. auris, 38 for T. otitidis, and 28 for A. otitidis. The most 
prevalent species was Staphylococcus auricularis (63 and 66 respectively), which 
was the third most prevalent in the culture-independent study by Frank et al 
(2003). This demonstrates how different colonisation can appear when using 
culture as opposed to molecular genetic techniques. S. auricularis has not been 
linked to OM as frequently as the other species and therefore is not included to a 
great extent in this study. 
T. otitidis and C. auris share many characteristics. This makes them difficult to 
tell apart using standard clinical tests. The API Coryne system is a rapid but quite 
accurate method for the identification of Corynebacterium species (Soto et al. 
1994). However, this system cannot tell T. otitidis and C. auris apart, with the API 
Coryne system numerical profile for both species very often 210004 (Gomez-
Garces et al. 2004). Despite this, relatively simple morphological and metabolic 
characteristics allow their differentiation (Gomez-Garces et al. 2004). 
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Table 1.1 Diversity of microbiota associated with human ear canals, 
identified using 16S rDNA culture-independent techniques (Frank, et al., 
2003). 
   
Nearest relative
a
 Clade
b
 % ID
c
 No. of 
clones
d
 
% of 
total 
 
A. otitis Low G + C 96-98 1,221 56.71 
C. otitidis Actinobacteria 96-99 440 20.44 
S. auricularis Low G + C 98-99 212 9.85 
C. auris Actinobacteria 98 67 3.11 
Tilletiaria anomala Eucaryote 94-95 65 3.02 
P. acnes Actinobacteria 99 35 1.63 
Corynebacterium sp. strain 61720 Actinobacteria 97 17 0.79 
M. obscurus fungus Eucaryote 94-97 10 0.46 
Stephanoascus ciferrii Eucaryote 98 8 0.37 
Trhypochthonius tectorum Eucaryote 91 8 0.37 
S. epidermidis Low G - C 95 6 0.28 
Fusobacterium periodonticum Fusobacteria 98 4 0.19 
Homo sapiens (mitochondrion) Plastid 97 4 0.19 
Pseudomonas lanceolata γProteobacteria 99 4 0.19 
Streptococcus gordonii Low G + C 99 4 0.19 
Aspergillus fumigatus Eucaryote 96 3 0.14 
P. pubis fungus Eucaryote 99 3 0.14 
Sclerotium sp. strain BSC-97 Eucaryote 96 3 0.14 
Enterobacter sp. strain B509 γProteobacteria 99 3 0.14 
Staphylococcus hominis Low G - C 90 3 0.14 
Kocuria erythromyxa Actinobacteria 94 2 0.09 
Uncultured bacterium strain BPC009 Actinobacteria 95-98 2 0.09 
Enterobacter agglomerans γProteobacteria 99 2 0.09 
Bacillus licheniformis Low G - C 98 2 0.09 
Streptococcus sp. oral strain B5SC Low G - C 98 2 0.09 
Alpha proteobacterium strain VUN10077 αProteobacteria 99 1 0.05 
Uncultured bacterium 16S rRNA ß Proteobacteria 98 1 0.05 
Acinetobacter sp. γProteobacteria 98 1 0.05 
Haemophilus paraphrophilus γProteobacteria 96 1 0.05 
Brevibacterium avium Actinobacteria 98 1 0.05 
Brevibacterium sp. Actinobacteria 98 1 0.05 
Corynebacterium sp. strain X82493 Actinobacteria 95 1 0.05 
Dietzia maris Actinobacteria 95 1 0.05 
Gram-positive bacterium strain Wuba45 Actinobacteria 97 1 0.05 
Human oral bacterium strain AC1 Actinobacteria 98 1 0.05 
Synechococcus sp. strain ATCC 700246 Cyanobacteria 95 1 0.05 
Tetranychus urticae Eucaryote 95 1 0.05 
Abiotrophia defectiva Low G + C 96 1 0.05 
Carnobacterium sp. strain LV62LW1 Low G + C 92 1 0.05 
Staphylococcus piscifermentans Low G + C 96 1 0.05 
Streptococcus mitis Low G + C 99 1 0.05 
Streptococcus sp. oral clone BW009 Low G + C 99 1 0.05 
Veillonella sp. oral clone X042 Low G + C 98 1 0.05 
Uncultured bacterium strain WCHA2-01 OP11 100 1 0.05 
Uncultured bacterium 16S rRNA, strain 
BD7-4 
OP11 87 1 0.05 
Total   2,150 100.00 
 
a
 Based on BlastN search.  
b
 Kingdom (eucaryote)- or division (bacteria)-level phylogenetic affiliation.  
c
 BlastN score. ID, identity.  
d
 Total number of clones screened in all libraries. 
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 Nasopharyngeal bacteria 1.2.2
The bacteria of the NP consist of benign commensals and asymptomatic 
pathogens (Harrison et al. 1999). It is known to be a reservoir for potentially 
pathogenic species of the upper respiratory tract (URT), and has therefore been 
more extensively studied than the OE. 
A recent metagenomic analysis was carried out on the bacterial DNA from the NP 
of 96 healthy 18 month olds. A metagenomic analysis allows the identification of 
the species present in a polymicrobial population through the use of 454 
pyrosequencing, without initial isolation of the species. The top 30 operational 
taxonomic units (OTU), representing 30 different DNA sequences and therefore 
bacterial species, are presented in Table 1.2. It is important to note that the top 
three most common OTUs at the genus level are of the Moraxella genus, 
Streptococcus genus, and H. influenzae (identified to the species level). 
The carriage rates and dominance of species in the NP is determined by a number 
of factors. The presence of other bacteria, exposure to cigarette smoke, age, 
presence of respiratory illnesses, season, use of day care facilities, sibling number, 
diet and sleeping position are all noted factors.  
Interactions between colonising bacteria have been shown to influence the NP 
carriage of potentially pathogenic bacteria. Non-pathogenic bacteria, such as α-
haemolytic streptococci, Peptostreptococcus anaerobius and Prevotella 
melaninogenica, are known to interfere with the ability of potential pathogens, 
such as S. pneumoniae, H. influenzae, and M. catarrhalis, to colonise this area 
(Brook & Gober 1998). This could demonstrate the importance of „interfering 
organisms‟ in inhibiting pathogen colonisation. These interactions are important 
to understand in order to treat OM appropriately. 
Smoking has been shown to have a marked effect on the colonising organisms of 
the respiratory tract (Brook 2011). Affecting both the smoker and those exposed 
second hand, smoke has been shown to decrease the number of organisms with 
interfering capacities, therefore increasing the number of nasopharyngeal 
colonising pathogens with the potential to cause OM. H. influenzae, S. 
pneumoniae and M. catarrhalis, are seen to colonise in increased numbers in 
children who are prone to OM (Brook & Gober 1998).  
  
 
7
 
Table 1.2 Thirty most common OTUs (‘species-level’ phylotypes), ranked by absolute presence among the ~1100000 reads(Bogaert et al. 2011).
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Using culture techniques, Harrison et al (1999) showed how the bacterial species 
of the NP changed as infants grew, and tested for variations in bacterial 
colonisation between periods of upper respiratory tract infections (URTI) 
(Harrison et al. 1999). Statistically significant differences in bacterial carriage 
were found when comparing NP populations in children <3 months of age to 
those >3 months of age, indicating age has an effect on the carriage of many 
bacterial species (Harrison et al. 1999).  
When comparing infants with URTI to age and gender matched URTI-free 
controls, it was shown that URTI had little effect on bacterial carriage in the NP 
(Harrison et al. 1999). Statistically significant differences were found only in 
Staphylococcus epidermidis (a benign commensal), M. catarrhalis (referred to in 
this paper under its previous name, Branhamella catarrhalis) and α- or non-
haemolytic streptococci. The use of culture techniques may limit these results; 
though diverse growth conditions were used to minimise potential bias (Harrison 
et al. 1999). 
Historically, NP cultures were used in an attempt to predict the pathogens present 
in the middle ear (Gehanno et al. 1996). However, evaluation of this technique 
found that pathogens in the NP did not directly correspond to their involvement in 
OM. It was found however, that a negative culture for any NP pathogens had a 96% 
predictor value in determining the lack of pathogens in the MEE (Gehanno et al. 
1996). This means, that if no pathogens were cultured from the NP, then the 
prediction that there were no pathogens in the middle ear was accurate 96% of the 
time. 
1.3 Pathogens of middle ear disease 
 Koch’s postulates 1.3.1
Historically, Koch‟s postulates determined whether or not a microorganism was 
causative of a disease (Fredricks & Relman 1996). Briefly, Koch‟s postulates state 
that for an organism to be a pathogen; the parasite occurs in every case of the 
disease; and exists in no other disease by chance or asymptomatically; and that it 
can be isolated in pure culture, re-inciting disease state upon introduction to a new 
susceptible individual (Fredricks & Relman 1996). 
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These postulates were published in the late 18
th
 century. Advancements in 
technology that have allowed detection of organisms without first isolating in pure 
culture, and the fact that viruses cannot be grown in pure cell-free culture, have 
led to their re-evaluation (Fredricks & Relman 1996). Using OM as an example, 
known pathogens can colonize the NP asymptomatically, and there are instances 
of bacteria-free infections, facts which go against Koch‟s postulates (Vergison 
2008). 
 Nasopharyngeal pathogens and viruses in otitis media 1.3.2
Early in the 20
th
 century, group A streptococcus were the leading cause of OM in 
children (Vergison 2008). Good oral hygiene and the use of antibiotics have led to 
a shift in the etiology of the disease. Further shifts have been caused by the 
introduction of vaccines, such as the 7-valent pneumococcal conjugate vaccine 
(PCV7) effective against targeted serotypes of S. pneumoniae. Predominantly, the 
NP pathogens M. catarrhalis, H. influenzae and S. pneumoniae make up the triad 
currently causing OM. Despite vaccine availability differing between countries, 
and causing differences in the epidemiological landscape, this triad are still the 
leading OM pathogens globally (Vergison 2008). Table 1.3 shows the frequency 
in which these three organisms are cultured in MEEs. 
S. pneumoniae can invade the URT in both normal and immune impaired 
individuals (Murphy et al. 2009). The large carriage rate (see section 1.3.4 of this 
literature review for examples) in healthy individuals has a function in facilitating 
its transmission between individuals, and could cause problems in those with less 
immunity against them. This species has a polysaccharide capsule, with a function 
in increasing pathogenicity (Murphy et al. 2009). 91 different specific 
polysaccharide capsules, or „serotypes‟, of S. pneumoniae exist. The capsule has a 
function in protecting the organism from host immune responses, which can 
increase pathogenesis in cases of AOM and other Streptococcus related ailments 
(Murphy et al. 2009).  
Between 1999 and 2002, it was found that cases of AOM caused by non-PCV7 
targeted serotypes of S. pneumoniae increased from 12% to 32% (Vergison 2008). 
Further, AOM caused by non-typeable H. influenzae increased in incidence. Non-
typeable H. influenzae are the non-encapsulated serotype of this species, and are 
thought to cause mucosal infections, such as OM (Murphy et al. 2009). Although 
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they can colonise the NP asymptomatically, the observation has been made that 
colonisation in the first few months of life is associated with recurrent OM.  
For decades, M. catarrhalis was thought to have very little or no pathogenic 
abilities. This was concluded despite its detection more often than the other two 
pathogens in sputum samples from sufferers of the URTI chronic obstructive 
pulmonary disease (COPD) (Murphy et al. 2009). It was later discovered to be an 
important pathogen in disease exacerbation. Further, M. catarrhalis has been 
found in the middle ear fluid of OM sufferers. With a potential function in 
increasing the biofilm, and by possibly providing passive antibiotic resistance to 
other species, M. catarrhalis is now seen as an important contributor to OM 
infections (Armbruster et al. 2010).  
Table 1.3 Pathogens cultured from middle ear effusions (Poetker et al., 2005). 
 
Pathogen
Total 
effusions 
(n  = 233)
Total 
isolates 
(n  = 148)
Right 
effusions 
(n  = 118)
Right 
isolates 
(n  = 65)
Left 
effusions 
(n  = 115)
Left 
isolates 
(n  = 83)
No growth 99 (42.5) 61 (51.7) 38 (33)
Staphylococcus  (NOS) 38 (16.3) 38 (25.7) 14 (11.9) 14 (21.5) 24 (20.9) 24 (28.9)
Haemophilus influenzae 24 (10.3) 24 (16.2) 12 (10.2) 12 (18.5) 12 (10.4) 12 (14.5)
Moraxella catarrhalis 15 (6.4) 15 (10.1) 12 (10.2) 12 (18.5) 3 (2.6) 3 (3.6)
Neisseria meningitidis 11 (4.7) 11 (7.4) 5 (4.2) 5 (7.7) 6 (5.2) 6 (7.2)
Staphylococcus aureus 11 (4.7) 11 (7.4) 3 (2.5) 3 (4.6) 8 (7) 8 (9.7)
Corynebacterium 11 (4.7) 11 (7.4) 4 (3.4) 4 (6.2) 7 (6.1) 7 (8.4)
Staphylococcus epidermidis 9 (3.7) 9 (6.1) 2 (1.7) 2 (3.1) 7 (6.1) 7 (8.4)
Streptococcus pneumoniae 6 (2.6) 6 (4.1) 3 (2.5) 3 (4.6) 3 (2.6) 3 (3.6)
Streptococcus mitis 3 (1.3) 3 (2) 1 (0.8) 1 (1.5) 2 (1.7) 2 (2.4)
Staphylococcus warneri 3 (1.3) 3 (2) 2 (1.7) 2 (3.1) 1 (0.9) 1 (1.2)
Staphylococcus capitis 2 (0.8) 2 (1.4) 1 (0.8) 1 (1.5) 1 (0.9) 1 (1.2)
Streptococcus salivarius 2 (0.8) 2 (1.4) 1 (0.8) 1 (1.5) 1 (0.9) 1 (1.2)
Rare Coagulase Negative
Staphylococcus 2 (0.8) 2 (1.4) 1 (0.8) 1 (1.5) 1 (0.9) 1 (1.2)
Candida species 2 (0.8) 2 (1.4) 0 0 2 (1.7) 2 (2.4)
Leuconostoc 2 (0.8) 2 (1.4) 0 0 2 (1.7) 2 (2.4)
Escherichia coli 1 (0.4) 1 (0.7) 1 (0.8) 1 (1.5) 0 0
Bacillus species 1 (0.4) 1 (0.7) 1 (0.8) 1 (1.5) 0 0
Staphylococcus saprophyticus 1 (0.4) 1 (0.7) 1 (0.8) 1 (1.5) 0 0
Streptococcus pyogenes 1 (0.4) 1 (0.7) 1 (0.8) 1 (1.5) 0 0
Branhamella caterrhalis 1 (0.4) 1 (0.7) 0 0 1 (0.9) 1 (1.2)
Aerococcus viridans 1 (0.4) 1 (0.7) 0 0 1 (0.9) 1 (1.2)
Lactis cremoris 1 (0.4) 1 (0.7) 0 0 1 (0.9) 1 (1.2)
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Many upper respiratory viruses are commonly associated with OM. 20% of AOM 
cases are thought to be caused by viruses alone, while another 65% of infections 
involve co-infection with a virus and bacteria species (Vergison 2008). Viruses 
with associations to OM include Human rhinovirus, respiratory syncytial virus 
(RSV), influenza viruses A and B, and parainfluenza 1, 2 and 3. These are thought 
to play a role in facilitating bacterial invasion of the middle ear cavity (Binks et al. 
2011). It is environmental factors, including the presence of a virus, which can 
cause commensal bacteria of the NP to become primary pathogens of OM 
(Bakaletz 2009). 
Studies have shown that certain strains of M. catarrhalis are able to adhere to 
epithelial cells much more effectively when an RSV infection is also present 
(Binks et al. 2011). Cilial beating and the human immune system normally keeps 
potential pathogens of OM in the NP. However, it is thought that viral infection 
can contribute to inflammation in the Eustachian tube, decreasing cilial beat 
frequency and the ability of the epithelial cells to resist bacterial invasion. This 
may lead to Eustachian tube ascension by opportunistic pathogens and therefore 
OM (Binks et al. 2011). 
Using animal models, it has been shown that co infection with a virus, such as 
influenza or parainfluenza, and a bacterial pathogen, such as S. pneumoniae, left 
animals more susceptible to developing OM than those with only the bacteria 
present (in the NP) (Murphy et al. 2009). These two viruses possess 
neuraminidase activity which removes the sialic acid from host cell receptors. 
This may provide an avenue for S. pneumoniae attachment to the cell surface and 
subsequent spread of the bacterium. If this activity was used on the mucosa of the 
Eustachian tube, this would impair functioning and increase the likelihood of its 
ascension and subsequent OM (Bakaletz 2009).  
 Outer ear bacteria and otitis media 1.3.3
It has been postulated that the conditions of the middle ear can determine whether 
bacteria becomes a coloniser or a pathogen (Gomez-Garces et al. 2004). For 
example, the inflammation cause by a primary middle ear infection, and/or the 
antibiotics prescribed to combat it, may lead to an imbalance of the microbial 
flora. This imbalance may cause a change in the previously harmless bacteria, 
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causing them to overgrow and extend into a pathogenic role (Gomez-Garces et al. 
2004). 
The possibility of OE commensal bacteria crossing through the inflamed tympanic 
membrane into the middle ear cavity during an initial infection and subsequently 
complicating treatment is a leading point in this research. Ruptures of the ear 
drum either from previous grommets or from spontaneous rupturing during 
infection, is another possible avenue (Frank et al. 2003). How regularly these 
spontaneous ruptures occur during AOM is unknown.  
As previously mentioned, the three OE bacteria with controversial associations to 
OM are A. otitidis, C. auris, and T. otitidis (Holzmann et al. 2002; Gomez-Garces 
et al. 2004; Ashhurst-Smith et al. 2007; Harimaya et al. 2007). All have been 
cultured from the MEEs of patients with OM. There is a possibility that the OE 
bacteria present in samples obtained from the middle ear cavity may be 
contaminates from the OE cerumen (Frank et al. 2003). Though, the occasional 
intracellular location of A. otitidis could be used as evidence to prove that A. 
otitidis at least enters the middle ear in one way or another during OM (Faden & 
Dryja 1989).  
To test the theory of A. otitidis as a true OM pathogen, an enzyme-linked 
immunosorbent assay (ELISA) was used to measure the level of proinflammatory 
cytokines and chemokines released when it was the sole pathogen. Results were 
then compared with the levels present when the known pathogen S. pneumoniae 
caused the infection (Harimaya et al. 2009). These proinflammatory molecules 
increased in a similar manner between both A. otitidis and S. pneumoniae, 
suggesting A. otitidis is a true pathogen of OM (Harimaya et al. 2009). 
A study that looked into the prevalence of A. otitidis in MEE during cases of 
AOM and OME found that it occurred more regularly in OME cases (Leskinen et 
al. 2002). They postulated that this correlation to OME could mean A. otitidis was 
a factor in increasing chronicity and have consequences in prolongation of 
inflammation. Further, A. otitidis has been found in the NP and MEE of otitis 
prone children, more often than in non-otitis prone children, providing evidence 
towards a role in chronicity (Harimaya et al. 2006) The increased colonisation of 
the NP by this organism may also have relevance to OM episodes, or could 
simply be the opportunistic colonisation of the area when it becomes accessible. 
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If A. otitidis is found to be a true pathogen of OM, or a secondary infectious agent, 
this could have a significant impact on how we treat OM. This is because A. 
otitidis displays resistance to amoxicillin/clavulanate, the sulfa drugs, and 
erthyromycin, all prescribed for the treatment of OM (Coates 2007).  
C. auris is frequently penicillin resistant, with a MIC of >1 mg/L (Gomez-Garces 
et al. 2004). If this bacterium played a role in OM, this could complicate penicillin 
treatment. C. auris’ association with OM is also unknown and controversial, with 
many studies concluding it is part of the normal OE flora (Holzmann et al. 2002). 
This despite Corynebacterium spp. and C. auris itself being cultured from the 
MEE of patients with OM (see Table 1.3) (Stuart et al. 2003; Poetker et al. 2005).  
T. otitidis is thought to be found exclusively in the OE, and whether it is a true 
pathogen of OM is a controversial possibility (Gomez-Garces et al. 2004). It was 
originally isolated from patients suffering from OM under the genus 
Corynebacterium. The classification of T. otitidis under a different genus 
(Turicella) is due to the chemotaxonomic and phylogenetic distinctiveness of this 
bacterium from its coryneform counterparts (Funke et al. 1994).  
 Global differences 1.3.4
Worldwide, the distribution of OM pathogens from the NP has been seen to differ 
(Vergison 2008). A comparison of a number of aetiology results from around the 
world by Vergison et al (2008) indicated that H. influenzae and S. pneumoniae 
dominate the microbial flora in patients with OM, with M. catarrhalis coming 
third. Group A streptococcus were the most geographically distinct species, with a 
range of 1% to 5% of cases containing this species worldwide (see Figure 1.2).  
Carriage rates of the three major NP pathogens have been shown to be highly 
diverse depending on geographic location, age group and socioeconomic status 
(Garcia-Rodriguez & Martinez 2002).  Using S. pneumoniae as an example, the 
lowest carriage rate was a group of 261 Swedish adults, at only 0.8%. A Swedish 
group of 620 healthy children, in contrast, had a carriage rate of 52%. This 
suggests the possibility of an immune response in the former. The highest carriage 
rate was seen in 102 Gambian children, of 87.2%, demonstrating the effect of 
socioeconomic status on colonisation. (Garcia-Rodriguez & Martinez 2002). 
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Figure 1.2 Distribution of key OM pathogens worldwide (Vergison., 2008). 
Results compiled from a number of references, stated above. 
Vaccination availability differs globally and can influence the etiology of the 
disease. PCV7 is effective against 7 of the 91 serotypes of S. pneumoniae, and is 
used in the fight against pneumococcal species colonisation. This vaccine was 
licensed for use in 2000, and has been widely used since then (National Network 
for Immunization Information  2010).  
PCV7 became available to Taiwanese children in October of 2005 (Kuo et al. 
2011). As vaccination rates increased through the Taiwanese population, a study 
looked at the presence of S. pneumoniae in 6057 children. No significant decrease 
in the carriage rate of S. pneumoniae in the NP was found between July 2005 and 
July 2008, possibly indicating the replacement of vaccine-serotypes with non-
vaccine serotypes.  
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A Lebanese study on OM pathogens demonstrates the importance of moderation 
of antibiotic treatment (Nasser et al. 2011). In Lebanon, antibiotics are available 
without a prescription, leading to the potential for overuse. This study found that 
about half of the H. influenzae cultured from patients with OME were beta-
lactamase-negative, ampicillin resistant strains. It is thought this resistance comes 
from altered penicillin binding proteins, which lowers the affinity for β-lactams 
(Nasser et al. 2011). More alarming is the pattern of increased antibiotic resistance 
of pathogens from children that are regularly exposed to cigarette smoking, a 
habit ubiquitous in many societies. 
Looking specifically at New Zealand children, the microbiology of the NP and 
OE has not been studied extensively. However, two studies have looked at 
bacteria present in MEEs. One study on Auckland children from 1996 used 
culture techniques to determine the pathogens present in MEEs (Watson et al. 
1996). Of 105 ears, 67 were culture negative. The majority of culture positive 
samples were of the three known pathogens, indicating New Zealand‟s is also 
caused by this triad.  
A more recent study looked at the colonisation of S. pneumoniae, H. influenzae, 
M. catarrhalis and A. otitidis in the MEEs of Hamilton children in New Zealand 
(Cecire et al. 2009). 98 specimens were collected, and using non-culture 
techniques, 160 positives were found across these four bacteria. This demonstrates 
the polymicrobial nature of infection, and further shows that New Zealand 
children have a high carriage rate of NP pathogens. For example, of 98 specimens, 
35% were positive for S. pneumoniae. This is a similarly high carriage rate as seen 
in global studies (Garcia-Rodriguez & Martinez 2002) 
 Biofilms and Antibiotic Resistance 1.3.5
Biofilms exist in nature as complex communities of bacteria encased in an 
exopolymeric matrix (Hall-Stoodley et al. 2006). They are often closely 
associated to a surface, such as a grommet, but can also form on mucosal surfaces, 
such as those present in the Eustachian tube or middle ear (Murphy et al. 2009). 
These polymicrobial communities have been shown to have a different 
transcriptome, a reduced growth rate and an increased frequency of genetic 
material exchange by horizontal gene transfer, when compared to free living 
organisms. This allows them to optimise their existence to account for growth 
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limiting environments that occur in situ. Sometimes antibiotic resistance genes are 
shared, potentially complicating treatment (Murphy et al. 2009). 
MEEs from patients with chronic OM, such as OME and rOAM, have previously 
been visualised using a confocal scanning laser microscope. These images 
supported the hypothesis that these chronic forms of middle ear infection are 
biofilm-related (Hall-Stoodley et al. 2006). As well as providing a physical 
impediment against antibiotic attack, enzymes such as β-lactamase have been 
recognised within some biofilms (Fergie et al. 2004). β-lactamase targets the β-
lactam ring present in antibiotics such as ampicillin, inhibiting its antibacterial 
properties. Antibiotic susceptible bacteria may therefore be protected from 
destruction due to the presence of resistance enzymes produced by other species 
in the biofilm extracellularly. 
A possible example of this has been observed between H. influenzae and M. 
catarrhalis in vitro (Armbruster et al. 2010). As observed using scanning electron 
microscopy, when infected with both species a biofilm is formed which is more 
substantial than when formed by the species individually. As well as a physical 
barrier to immune response, H. influenzae is further provided with passive 
resistance to antibiotics such as β-lactam, as M. catarrhalis produces the enzyme 
β-lactamase directly into the biofilm (Armbruster et al. 2010).  
Further support for the biofilm model comes from experiments looking at the 
effects of co infection of a viral pathogen and S. pneumoniae on chinchilla NP and 
ME biofilm status (Hoa et al. 2009). Using scanning electron microscopy, the 
middle ears of control chinchillas and infected chinchillas were compared. Of 
those infected chinchillas observed to have developed OM, NP biofilms were 
found in 83% and ME biofilms were found in 67%. All animals with ME biofilms 
also had NP biofilms (Hoa et al. 2009). When compared to controls, Chinchillas 
with AOM demonstrated a higher proportion of NP biofilms. This demonstrates 
the influence the NP flora and biofilm status has on AOM development. 
Bacteria in biofilms tend to have a slow growth rate and low metabolic activity, 
which could explain the large proportion of culture negative but PCR positive 
samples (Rayner et al. 1998). It could also show the ability of biofilms to retard 
the degradation of DNA and mRNA, in which case DNA based technologies may 
identify bacteria long dead from antibiotic treatments, as its genomic remains 
were still present in the biofilm (Fergie et al. 2004). However, Rayner et al (1998) 
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provided solid evidence for the presence of metabolically active H. influenzae in a 
culture negative samples by detecting unstable mRNA molecules which would not 
have been present if the organism had been long dead (Rayner et al. 1998).  
1.4 Treatment of otitis media 
 Current treatments 1.4.1
 Vaccines 1.4.1.1
As previously mentioned, a 7-valent pneumococcal conjugate vaccine (PCV7) is 
currently in use (Morris et al. 2009). This targets S. pneumoniae, an important 
pathogen of OM. The use of this vaccine has been shown to decrease the 
colonisation of the serotypes of S. pneumoniae that it targets, but has led to an 
increase in the non-targeted serotypes, potentially counteracting the decrease in 
other serotypes (Vergison 2008). Despite this, it has been shown that vaccinations 
can decrease the incidence of OM by about 6%, and markedly decrease the 
number of ventilation tube insertions by about 24% (Fireman et al. 2003). 
An unfortunately side effect of vaccination and antibiotic treatment has been the 
increase in prevalence and the spread of a penicillin resistant S. pneumoniae strain. 
This has complicated treatment and modified the epidemiological landscape of 
OM (Vergison 2008) A newly developed 13-valent pneumococcal conjugate 
vaccine (Prevnar-13), which targets 13 pneumococcal serotypes, has recently been 
approved for routine vaccination (Sucher et al. 2011). As this vaccine targets six 
more serotypes than PCV7, it is hoped that its introduction will decrease both the 
serotype replacement effect seen when using PCV7 and the spread of resistant 
strains.  
Vaccines directly for the prevention of OM are not currently in use, as the 
causative agents can differ quite drastically between cases (Arar et al. 2008). 
Since the introduction of the aforementioned vaccine, and other polyvalent 
vaccines, the most commonly isolated pathogen of AOM has become H. 
influenzae (Coates 2007).  
 Antibiotics and surgical interventions 1.4.1.2
Antibiotic resistance is a major problem in the fight against OM. For non-severe 
infections, the use of antibiotics is restricted. Watchful waiting remains a 
treatment for OM, as often these infections can resolve themselves (Morris et al. 
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2009). However, a blind trial comparing the use of amoxicillin-clavulanate to a 
placebo showed that the children given the antimicrobial therapy had better 
resolution of the disease (Tahtinen et al. 2011). Amoxicillin-clavulanate is a drug 
that demonstrates activity against β-lactamase-producers as well as penicillin 
resistant S. pneumoniae strains (Hoberman et al. 2002). A similar study by 
Hoberman et al. (2011) compared the efficiency of amoxicillin-clavulanate to the 
use of a placebo on AOM (Hoberman et al. 2011). 16% (amoxicillin-clavulanate) 
versus 51% (placebo) of children persisted to have signs of AOM after 10 – 12 
days.  
These studies may have been skewed to favour antibiotic treatment by their 
stringent selection criteria resulting in the inclusion of children with more 
advanced OM. Therefore, their conclusion may indicate that children with more 
severe OM should be treated with antibiotics, and watchful waiting continue to be 
used in monitoring less severe cases for spontaneous resolution or increasing 
severity. 
In the more severe cases of rAOM, the Centre for Disease Control and Prevention 
(CDC) recommends treatment with three sequential courses of antibiotics. These 
are amoxicillin/clavulanate (as discussed earlier), cefuroxime and ceftriaxone. 
This is to treat against bacterial species that may be resistant to one or two of 
these, but not all (Coates 2007). 
Antibiotic treatment should be prescribed carefully, as it can increase the reservoir 
potential of the NP by facilitating the survival of antibiotic resistant organisms. 
For example, if broad spectrum antibiotics are used, numbers of competing or 
„interfering‟ organisms could be decreased (Hoa et al. 2009). This could decrease 
the resistance capabilities of the respiratory system against pathogen colonisation. 
Interfering commensal organisms are needed to compete against pathogenic 
bacteria for establishment in the child‟s respiratory system (Brook & Gober 1998).  
Using culture techniques, Brook & Gober (1998) determined the efficiency of two 
regularly used antibiotics against OM (amoxicillin/clavulanic acid, and cefprozil) 
for efficacy in killing OM pathogens while leaving non-pathogenic bacteria 
unscathed (Brook & Gober 1998). It was shown that, while both antibiotics 
attacked and killed non-pathogenic interfering bacteria, cefprozil was more 
specific to the pathogenic bacteria. However, amoxicillin/clavulanic acid remains 
a staple in treatment of OM. Samples of the NP were not taken after an extended 
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period of time to determine the re-establishment of pathogenic bacteria after 
antibiotic treatment, nor were future bouts of ear infection reported, limiting 
results. 
Surgical interventions are widely used on infections that fail to respond 
effectively to antibiotics. Insertion of a ventilation tube (or grommet) is common 
practice in cases of rAOM and OME. This allows the release of the pressure built 
up behind the ear drum, due to the blocking of the Eustachian tube, and also may 
have a function to dry out the biofilm (Fergie et al. 2004). 
 Future treatments 1.4.2
OM caused by H. influenzae may prove to be vaccine preventable (Morris et al. 
2009). A pneumococcal- H. influenzae protein D conjugate vaccine that could 
potentially vaccinate against 11 serotypes of S. pneumoniae and non-typeable H. 
influenzae, is currently being assessed for clinical use (Haggard 2008). These 
bacteria are both important pathogens of OM, and therefore this could potentially 
be the first vaccine against OM itself. Trials on this vaccine have already been 
associated with a reduction in the risk of developing OM by 34% (Jansen et al. 
2009). This is much more substantial than the modest 6-7% reduction in OM 
episodes reported from the use of PCV7 (Binks et al. 2011). 
A potential target for a vaccine against A. otitidis has been identified in the form 
of an acidic capsule polysaccharide. This capsule may provide a highly charged 
cell surface, and some form of antibiotic resistance potentially important in the 
pathogenicity of the organism (Arar et al. 2008). If vaccines against the primary 
pathogens of OM were to become more frequently administered, A. otitidis could 
fill the gap this creates and itself become a primary infectious organism. Therefore, 
it is important to assess possible targets of these other organisms pre-emptively, as 
it may become necessary to administer both vaccines for effective OM protection. 
1.5 Research outline 
Using both molecular genetic techniques adapted from those previously described 
(Hendolin et al. 1997), and culture techniques, this research looks to determine the 
presence of six bacteria (H. influenzae, S. pneumoniae, T. otitidis, C. auris, A. 
otitidis and M. catarrhalis) linked to OM in the NP, MEE and OE. Emphasis will 
be on non-culture based techniques as to avoid culture bias and potential bias 
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caused by incomplete antibiotic profiles of the children involved. Comparisons 
will be made between the presence/absence of these six bacteria between children 
with OM and OM-free control patients, and between studied body sites. 
Polymicrobial status between the groups and studied sites will also be analysed. 
Culture techniques will be used on a subset of samples to determine species 
prevalence beyond that of the six species of interest. This will provide information 
on the species present in the NP, OE and MEE that are culture-viable.  
To further determine microbial diversity of these areas, a Sau-PCR microbial 
profiling technique will be used. This uses a restriction enzyme to cut at specific 
sites to create a banding pattern of which comparisons can be made between the 
differences/similarities of the microbes present between sampling variables. 
Cloning of the brightest bands (and therefore the most prevalent DNA sequences) 
will be undertaken in an attempt to identify the more dominant species. 
The vaccination status of all participating children will be compared with the 
prevalence of S. pneumoniae in their studied sites in an attempt to determine 
vaccination efficiency in firstly preventing S. pneumoniae colonisation, and 
secondly preventing OM. 
1.6 Techniques and Data analysis 
 Previously used techniques 1.6.1
Culture techniques are often used when determining the microbial composition of 
those areas involved in OM. Though this provides a definitive answer as to the 
culturable organisms present in the sample, organisms that are viable but non-
culturable could be falsely negative (Rayner et al. 1998). 
Multiplex PCR is used when studying specific bacteria involved in OM (Hendolin 
et al. 1997). A multiplex PCR utilizes a number of forward primers and one 
universal reverse primer to identify the presence of bacterial DNA. The size of the 
PCR products indicates which species were positively identified (Hendolin et al. 
1997). 
Microarrays are another valid option for identifying bacterial species present in 
polymicrobial samples. These microarrays work by the attachment of an 
oligonucleotide probe to a surface, such as glass, followed by the hybridization of 
complimentary DNA from targeted species in a mixed population. An example of 
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use can be seen in the paper by Cannon et al (2010) who used a low density 
oligonucleotide microarray to detect with high sensitivity and specificity, the 
presence of viral and bacterial DNA in a mixed population (Cannon et al. 2010). 
 Techniques of this study 1.6.2
To identify bacteria present in specimens taken from the NP, OE and the MEE, 
both culture techniques and non-culture based direct DNA extraction will be used:  
10% Columbia blood agar plates, 10% Columbia chocolate agar plates and brain 
heart infusion with foetal calf serum (BHI+FCS) broth will be used for culturing 
organisms. DNA will then be extracted from isolated cultures and subsequent 
sequencing of the 16S gene or DNA gyrase subunit B (gyrB) will allow for their 
identification. Alternatively, a Sau-PCR DNA will be used with a Sau-PCR 
microbial profiling technique for microbial community assessment. 
A Proteinase K enzyme lysis method will be utilized to extract genomic DNA 
directly from samples. This will be followed by a nested PCR for 
presence/absence analysis of six species of interest (A. otitidis, C. auris, T. otitidis, 
H. influenzae, M. catarrhalis, and S. pneumoniae). Nested PCR step 1 amplifies 
bases 63 to 941 of the 16S gene using universal primers. Then a second set of 
species specific primers, which anneal within the initial PCR product, will be used 
in a second cycle of amplification. Sequencing of PCR products obtained from a 
subset of the second round products will be completed to ensure accuracy of 
positive results. 
Sau-PCR will be used to further assess the microbiota in the sampled sites (Corich 
et al. 2005). This is in an attempt to further determine the community profile 
differences between the sites being analysed, and study groups (control and OM 
patients). Differences in banding patterns between culture and non-culture 
methods of analysis will also be assessed. 
 Data Analysis 1.6.3
A chi-squared test will be applied to determine the statistical significance of 
differences in colonisation of the six bacteria of interest between controls and 
patients in the same body site. 
Due to the lack of independence between left ear canal and right ear canal of each 
subject, as well as the lack of independence between the middle ears of the 
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patients, a chi-squared test cannot be used to find statistical significance between 
the NP and OE colonisation of species. A McNemar‟s test will therefore be used 
to determine if there is a statistical significant difference in colonisation between 
the NP and OE. The different study groups will be considered separately. 
1.7 Study objectives 
The main objectives of this study are as follows; 
1) To determine whether there is a correlation between the presence of otitis 
media pathogens/potential pathogens and the presence of OM.  
2) To determine whether the nasopharynx has any significant colonisation by 
A. otitidis, C. auris, or T. otitidis in either controls or OM patients. 
3) To determine colonisation differences between the sample sites. 
4) Using culture techniques, to determine the bacteria present in New 
Zealand children further than the six of interest. 
5) Using Sau-PCR, to compare the bacterial diversity present between the 
sites, the study populations, and the DNA isolation techniques (culture vs. 
non-culture). 
1.8 Hypothesis 
1) I hypothesise that samples from children with otitis media will have more 
M. catarrhalis, H. influenzae, and S. pneumoniae present in their NP than 
children without OM.  
2) I hypothesise that A. otitidis, T. otitidis and C. auris will be present in the 
nasopharynx and outer ears of OM children to a more significant level 
than OM-free control children. 
3) I hypothesise that there will be a difference in bacterial colonisation 
between the NP and OE in both OM patients and OM-free children. 
1.9  Null hypothesis 
1) There is no difference in colonisation of the six bacterium of interest when 
comparing otitis free controls and otitis media patients. 
2) There is no difference in colonisation of these six bacteria between the 
outer ear canal and nasopharynx. 
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2 Chapter 2: Materials and Methods 
2.1 Sample collection 
Ethical approval for this study was received from the University of Waikato 
Ethics Committee, and the Northern Y Regional Ethics Committee, Ministry of 
Health (Reference Number: NTY/11/03/029). Ethical approval information can be 
found in Appendix I. 
Prior to their procedure, parents of patients were approached either in the 
outpatient setting or in the admission unit for surgical procedures of the 
participating hospital by staff of the otolaryngology department. Information 
sheets and consent forms (Appendix I) were provided and any questions answered. 
In the case of controls, parents of patients were sent information sheets and 
consent forms by mail and then were contacted by telephone prior to the 
procedures to clarify queries. Some personal and medical details were obtained 
for help in analysis including: age, sex, ethnicity, operation undertaken, history of 
OM including number of ventilation tube insertions, right or middle ear fluid 
presence, and professional medical diagnosis. This information can be found in 
Appendix II. Participating health centres include Waikato Hospital, Hamilton, 
Southern Cross Hospital, Hamilton, Thames Hospital, Thames, and Anglesea 
Procedure Centre, Hamilton.  
Samples of the NP flora were taken via the nasal cavity using urethral swabs 
(Copan Italia). These were taken through a speculum inserted into the nose in an 
attempt to bypass the nasal cavity flora. Paediatric swabs (Copan Italia) were used 
for OE sampling of patients undergoing ventilation tube insertion. Flocked swabs, 
a newly developed swab for more sensitive microbial sampling, were not used in 
this research as they were not the standard of use (Goldfarb et al. 2009).  
MEEs were collected in patients that had a visible discharge using a shortened 
2mL syringe and a blunt 18G aspirating needle connected to wall suction. The 
sides of the outer ear canal were cleaned of cerumen beforehand, and avoided as 
best as possible during collection. The needle was discarded before transfer of the 
effusion into a sterile 1.7mL tube (Axygen). 
Control samples were collected at the same hospitals as above and in a similar 
manner, but from patients undergoing non-OM related procedures.  
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All swab samples were stored in Liquid Amies Medium, while MEEs were stored 
either in sterile saline solution or with no additives. All samples were labelled 
using a numbering system, and were stored in a -80°C freezer until required. 
2.2 Cultured isolates of six species of interest 
Live and growing cultures of H. influenzae, S. pneumoniae and M. catarrhalis 
were obtained from Pathlab Hamilton, while T. otitidis, C. auris and A. otitidis 
were sourced from the New Zealand Reference Culture Collection (NZRM) as 
freeze dried specimens. These freeze dried samples were streaked onto 10% blood 
agar, and grown at 37°C for 48 hours.  
DNA from all reference bacteria was extracted using the procedure detailed in 
section 2.3.2 for DNA isolation from cultured species. These isolated specimens 
were used to determine efficiency of DNA extraction protocols, specificity of 
primers, and the correct use of culture media. 
2.3 Culture analysis 
 Culturing of organisms 2.3.1
Swabs were streaked onto 10% Columbia blood agar plates and 10% Columbia 
chocolate agar plates. Some were also placed into 2mL brain heart infusion + 
foetal calf serum (BHI+FCS) broth. Alternatively, 100µL of MEE was added to 
the plates. These were incubated at 37°C (in a Precision incubator) for 7 days. 
10% Columbia blood agar plates were made as follows: In a 500mL SCHOTT 
bottle, 22g of Columbia blood agar (Difco
TM
) was added to 450mL of double 
distilled water (Barnstead). After a thorough mixing, the bottle was pressure 
cooked (duo) for twenty minutes, then put into a water bath (Julabo 12B) set at 
50°C until a temperature equilibrium was reached. In this time, a 50mL sample of 
sheep blood (Invitrogen – BL204BSL) was placed into a 37°C incubator 
(Precision).  
Once the temperature of the bottle and contents had reached approximately 50°C, 
the sheep blood was added. Approximately 30mL of the blood agar was then 
aseptically poured into standard 8cm petri dishes. 
10% Columbia chocolate agar was made using a similar procedure to the blood 
agar, only the blood was added when the agar was at approximately 80°C. After 
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blood addition, the bottle was returned to the water bath for 5 minutes with 
periodic swirling to ensure complete blood cell lysis. 
For BHI+FCS broth: 37 grams of BHI broth (Bacto
TM
) was added to 1L of 
distilled water in a 1L SCHOTT bottle. This mix was pressure cooked (duo) for 
twenty minutes, and then allowed to cool in a water bath to approximately 50°C. 
5.5mL of FCS was added to this sterilized BHI broth before this solution was 
filtered through a 0.2µm filter (Whatman). Aliquots of approximately 2mL were 
aseptically transferred into 5mL screw capped sterile tubes (SARSTEDT) using a 
sterile 3mL pipette. Unused broth was stored at 4°C until required.  
 DNA extraction from isolated species in culture 2.3.2
Species that grew on plates were isolated in pure culture for separate DNA 
analysis. Species that grew in FCS+BHI broth were first isolated from the broth 
by spinning for 30 seconds at 16.1rcf. The supernatant was completely removed 
before extraction commenced.  
DNA was extracted from cultured organisms using a lysozyme step followed by 
an SDS lysis protocol as follows: 
To a 1.7mL microcentrifuge tube, 90µL of TE and 10µL of 100mg/µL Lysozyme 
solution (100mg/mL) were added, followed by bacterial colonies using a 
disposable loop until the solution was cloudy. Vortexing was followed by 
incubation in a thermomixer at 37°C for 15 minutes at 800rpm. 350µL of SDS 
lysis solution was added, before thermomixing at 95°C for 10 minutes (800rpm). 
500µL of 5M Guanidinium thiocyanate (GITC), 55µL of sodium acetate (3M 
NaAc pH 5.2) and approximately 0.5mL of chloroform were added, mixed, and 
then put on a rotating wheel for 10 minutes. The DNA was precipitated using 
isopropanol and washed using 70% ethanol. 50µL of 1X TE was used for resus-
pension. DNA was quantified using an ND-1000 spectrophotometer (Nanodrop). 
2.4 DNA Quantification and Quality assessment 
DNA quantification results were obtained using an ND-1000 spectrophotometer 
(Nanodrop). Samples that were above 100ng/µL were diluted to this concentration 
in 1X TE. Purity of the DNA sample was assessed using the ratio between the 
260nm reading and the 280nm reading. A 260/280 ratio of 1.8 – 2 was considered 
ideal, however often this was unobtainable. The CTAB clean-up step was added 
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to remove as much of this contamination as possible, and all samples were 
analysed despite 260/280 readings.  
2.5 Identification of cultured organisms 
 Gram stain 2.5.1.1
Gram staining allows for the differentiation of gram positive and gram negative 
species, as well as the determination of morphology. In this study, gram staining 
was used to correctly identify two samples whose 16S sequence aligned with M. 
catarrhalis and M. nonliquefaciens. The former is morphologically a coccus, and 
the latter a rod. All reagents were from Ajax Finechem Pty Ltd, and were mixed 
locally. Staining procedure follows. 
Cells were heat fixed onto a microscope slide before a drop of crystal violet 
solution (2g Crystal violet (certified 90% dye content), 20 mL 95% ethanol 
(vol/vol), 0.8g ammonium oxalate, distilled water to 100mL) was added and left 
for one minute. Rinsing in tap water was followed by the addition of Gram‟s 
iodine (1.0 g iodine, 2.0g potassium iodide, 300mL of distilled water). This was 
left for two minutes before it was rinsed off and the cells decolourised using 95% 
ethanol (vol/vol). The final counterstain used was dilute carbol fuchsin. Carbol 
fuchsin is made using: 1g basic fuchsin, 5g phenol, 10mL absolute ethanol, and 
100mL water; this is then diluted 1:10 with distilled water to make dilute carbol 
fuchsin. This was applied to the cells for one minute before it was rinsed off, and 
the slide left in the 80°C incubator until dry.  
Visualisation was achieved using a Zeiss Axiostar plus microscope, at 1000x 
magnification under oil immersion.  
 16S Sequencing 2.5.1.2
The 16S gene was amplified using either the 63f and COM2R or 63f and DG74 
primer pairs (Table 2.1). Alternatively, the functional gene for DNA gyrase 
subunit B (gyrB) was amplified using specific gyrB forward and reverse primers. 
Reactions were completed in 0.2mL thin walled PCR tubes (Axygen). The 
reaction mixture used included 1X Buffer B (Solis Biodyne), Hot FIREPol DNA 
Polymerase (Solis Biodyne) at a concentration of 0.5U per 20µL reaction, 2mM 
MgCl2, and 250µM of each dNTP (A, G, C and T, Solis Biodyne). Primers were 
added at a concentration of 0.4µM. Parameters for the 63f/COM2R were as 
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follows: 95°C for 15 minutes, followed by 39 cycles of; 95°C for 20 seconds, 
60°C for 20 seconds, then 72°C for 1 minute. Reaction ended with a 5 minute 
extension step (72°C).  
Table 2.1 Forward and reverse primer sequences used throughout this 
research. They consist of both universal 16S or gyrB primers, and species 
specific forward primers. Primer names are abbreviations of species names 
as follows; A. otitidis primer: AO, C. auris primer: CA, H. influenzae primer: 
HI, Moraxella species primer: MS, S. pneumoniae primer: SP, T. otitidis 
primer: TO.  
 
When using the primer pair 63f and DG74, the reaction mix required treatment 
with Shrimp DNAse recombinant (usb) for 16S contamination removal. 
0.5U/20µL of Shrimp DNAse recombinant was added before incubation at 37°C 
for 15 minutes, then 80°C for 15 minutes. DNA was then added and the following 
PCR parameters used; 95°C for 15 minutes, followed by 10 cycles of: 95°C for 20 
seconds, 65°C for 20 seconds (decreasing by 1°C per cycle), then 72°C for 1 
minute and 30 seconds. This is followed by 25 cycles of: 95°C for 20 seconds, 
55°C for 20 seconds, then 72°C for 1 minute 30 seconds. Cycling is completed on 
a 72°C extension step for 5 minutes. 
PCR products were visualized on a 1% (w/v) TAE gel stained with ethidium 
bromide, as detailed in section 2.6.  
PCR products being sequenced were isolated using either the PEG purification 
method, or the rAPid Alkaline Phosphatase purification method. Sequencing used 
the 16S universal primers 702R, COM2R or 1195R (Table 2.1). 
Species Primer Sequence                                            
AO 5‟-GGG GAA GAA CAC GGA TAG GA-3‟ 
CA 5' - TGG ATA GGA CTG CTG GTT - 3'
HI 5‟-CGT ATT ATC GGA AGA TGA AAG TGC-3‟
MC 5‟-CCC ATA AGC CCT GAC GTT AC-3‟
SP 5‟-AAG GTG CAC TTG CAT CAC TAC C-3‟
TO 5' - AAC TGG GTC TAA TTC CCG - 3'
702R 5‟-CTA CGC ATT TCA CCG CTA CAC-3‟
COM2R 5' - CCG TCA ATT CCT TTG AGT TT - 3'
63f 5' - CAG GCC TAA CAC ATG CAA GTC - 3'
DG74 5'-AGG AGG TGA TCC AAC CGC A-3'
gyrB F 5'-CGI CCI GGK ATG TAY ATH GG-3'
gyrB R 5'-RMI CCW ACI CCR TGT AGI CCI CC-3'
1195R 5' GAC GTC RTC CNC DCC TTC CTC - 3'
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2.6 Agarose gel electrophoresis – visualisation of PCR 
products 
An Owl gel electrophoresis system was used to visualise PCR products. For both 
the nested PCR and cultured products, a 1% (w/v) agarose gel (usb) was cast 
using 1X Tris-Acetate-EDTA (TAE) buffer (40mM Tris acetate, 1mM EDTA) 
stained with ethidium bromide (1µg/mL). 10µL of amplified product was then 
added to the gel wells before being electrophoresed for approximately 30 minutes 
at 300A and either 100V (30mL gel) or 110V (100mL gel). A 100 base pair DNA 
ladder (Invitrogen) was used as a size reference and migrated with the DNA 
products. Visualisation occurred under UV light (TFX-35M, Life Technologies). 
If the DNA was to be cloned, as is the case with Sau-PCR products, a 2% TAE 
gel stained with RedSafe (5µL/100mL of 20,000X, Invitrogen) was used. The 
DNA was then visualised on a Safe Imager (Invitrogen). 
2.7 PCR product isolation for sequencing 
Two methods were used to isolate PCR products for sequencing. The first was a 
Polyethylene glycol (PEG) DNA isolation method, the second used a rAPid 
Alkaline Phosphatase protocol. 
The PEG PCR product isolation method follows: 
PCR product was added to a 1.7mL microcentrifuge tube. PEG solution (10.0g 
Polyethylene glycol 800, 7.3g NaCl), in a 1:1 ratio with the PCR product 
(generally 40µL), was further added. Solution was mixed and left at room 
temperature for 30 minutes, before centrifugation at 16.1 rcf for 10 minutes. The 
supernatant was removed before the addition of 1mL of 100% ethanol. 
Centrifugation at 16.1 rcf for 5 minutes followed. The precipitate was 
subsequently washed with 70% ethanol and resuspended in 10µLs of 1X TE. 
DNA was quantified using a Nanodrop (as detailed in section 2.4). 
The rAPid Alkaline Phosphatase protocol was as follows: 
To 10µL of PCR reaction components (including PCR product of interest), 0.5µL 
of Exonuclease I (10U) was added, along with 0.5µL of FastAP Thermosensitive 
Alkaline Phosphatase (1U). This was then heated at 37°C for 30 minutes, 
followed by 15 minutes at 85°C.  The concentration of the resulting purified PCR 
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product was estimated using a crude gel quantification method (detailed in section 
2.7.1).  
  Gel DNA quantification method after rAPid Alkaline 2.7.1
Phosphatase PCR product purification 
This method relies on the comparison between the brightness of a known 
concentration of DNA in the DNA ladder, and that of the unknown product.  
5µL of the recently purified PCR product was loaded onto a 1% (w/v) TAE 
agarose gel with the same volume of a 100bp DNA ladder (Invitrogen or Solis 
Biodyne) in an adjacent lane. The gel was then run on the Owl system at 100V 
and 300A for approximately 30 minutes. Comparisons were then made between 
the brightness of the bands to determine an approximate measure of DNA 
concentration. 
2.8 Isolation of genomic DNA directly from samples 
Genomic DNA for this study was isolated directly from the samples using an 
adapted proteinase K enzyme lysis method, followed by a DNA clean up using a 
Cetrimonium bromide (CTAB) protocol. 
Proteinase K enzyme lysis method: 
Swabs were either cut (urethral swabs), or snapped (paediatric swabs) into a 
1.7mL microcentrifuge tube (Axygen). In the case of a mucosal MEE, 100µL was 
added to the tube. 350µL of sodium dodecyl sulphate (SDS) lysis solution (1M 
tris pH 9, 50mM EDTA, 1% SDS), followed by 10µLs of Proteinase K solution 
was added to the swabs/effusion. The Proteinase K solution contained 0.06g of 
powder Proteinase K (final conc. 60µg/µL), 50mL glycerol, 0.01M Tris pH 8, 
0.2M calcium chloride (Ajax Finechem Pty Ltd) and was made up to 100mL 
using MQ-H20 (Barnstead). This was incubated in a thermomixer (Eppendorf) at 
56°C for 2 hours, shaking at 800rpm.  
A 0.6mL microcentrifuge tube, (Axygen) that has previously had a hole burnt into 
the bottom, was put inside a 1.7mL microcentrifuge tube, before the swabs were 
added to the smaller tube. Centrifugation (Biofuge pico Heraeus) at 16.1 rcf for 10 
seconds followed. The freed liquid was collected and returned to its respective 
tube, while swabs were appropriately discarded. 
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To this solution, 350µL of 5M lithium chloride (Ajax Finechem Pty Ltd) was 
added, and then an equal volume (approximately 750µL) of chloroform (Ajax 
Finechem Pty Ltd). After a vigorous mixing, the samples were put onto a rotating 
wheel (Labinco) for 15 minutes then centrifuged at 16.1rcf for 10 minutes. DNA 
was precipitated overnight using an equal volume of isopropanol (Ajax Finechem 
Pty Ltd) (approx. 750µL) and subsequently washed with 70% ethanol.  
500µL of 1X tris (hydroxymethyl) aminomethane (tris) ethylenediaminetetra-
acetic acid (EDTA) (1X TE: 10mM tris, 1mM EDTA pH 8) buffer was added in 
preparation for the following step in DNA purification. MEE samples did not 
require this clean up method, therefore only 20µL of 1X TE was added to these. 
CTAB purification step: 
30µL of 10% SDS (Ajax Finechem Pty Ltd) and 100µL of 5M sodium chloride 
(Ajax Finechem Pty Ltd) was added to the samples needing further purification. 
80µLs of CTAB/NaCl that had been in an 80°C incubator for 10 minutes was 
further added (10% CTAB in 0.7M NaCl). Incubation in a thermomixer at 65°C 
for 10 minutes followed. An equal volume of chloroform (Ajax Finechem Pty Ltd) 
was then added, mixed by inversion, and put on a rotating wheel for 10 minutes. 
Centrifugation followed at 16.1 rcf for 10 minutes. DNA was precipitated 
overnight using an equal volume of isopropanol before being washed with 70% 
ethanol. After resuspension in 20µL of 1X TE, DNA was quantified using a 
Nanodrop. 
Efficiency of this extraction method on the species of interest was assessed by 
running a swab over a mixed culture of all six species, storing in liquid Amies 
medium in a -80°C freezer, and then extracting the DNA the next day via the 
above method.  
2.9 Molecular genetic techniques (non-culture based) 
Both multiplex PCR and a nested PCR were trialled for efficiency in analysing the 
DNA from direct extraction. The primer pair 63f and COM2R were used in the 
first round of the nested PCR to amplify universal 16S DNA. Previously 
described primers specific for the 16S gene of A. otitidis, Moraxella species, H. 
influenzae, and S. pneumoniae were used, with the universal 16S 702R reverse 
primer, in both the multiplex PCR and the second round of the nested PCR 
(Hendolin et al. 1997).  
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C. auris and T. otitidis specific primers were designed using Primrose primer 
design technology, in conjunction with the rdp database and NCBI database for 
specificity assessment (Ashelford et al. 2002). These two primers had amine 
groups attached the 5‟ end, as they were initially designed to act as probes for a 
failed in-house microarray protocol. See Table 2.1 for primer sequences. 
 Moraxella catarrhalis vs. Moraxella nonliquefaciens  2.9.1
The Moraxella species primer was initially thought to be specific to M. 
catarrhalis (and was named MC, not MS). However, it was later discovered that  
M. catarrhalis and M. nonliquefaciens have near identical 16S sequence identity 
(sequence alignment demonstrated in Appendix III). Therefore, the primer 
described in Hendolin et al (1997) and used in this research has 100% identity not 
only with M. catarrhalis, but also with M. nonliquefaciens. This led to the 
reclassification of the M. catarrhalis results to that of Moraxella species in this 
current research. 
M. nonliquefaciens is present in the nasal cavity, and therefore NP samples may 
be contaminated with this species during sampling (Wilson 2005). However, use 
of a speculum to bypass the flora of the nasal cavity in order to sample only the 
flora of the NP decreases this likelihood. Culture results discussed in the coming 
chapter indicate the species initially positive for M. nonliquefaciens were 
identified instead as M. catarrhalis. This increases the likelihood that the majority 
of Moraxella spp. positives are for M. catarrhalis, as opposed to M. 
nonliquefaciens. 
 16S rRNA vs. DNA gyrase B 2.9.2
The use of DNA gyrase subunit B (gyrB) as the discriminating gene between the 
six species of interest was investigated (Watanabe et al. 2001). Protein coding 
genes can have higher sequence variation when compared to the 16S gene, and 
therefore allow further species distinction. Limited horizontal transfer of this gene 
between species makes it an ideal candidate for phylogenetic analysis and species 
identifier. Unfortunately, the gyrB gene had only been sequenced for the three 
known pathogens, and not the three OE bacteria. Species specific primers 
therefore could not be designed for this gene, and therefore was not suitable for 
use as a species identifier. 
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2.10 Primer binding sites 
 16S universal primers: 2.10.1
 63f binding position in the 16S sequence of the studied species 2.10.1.1
(listed as 3’ – 5’ of genomic sequence): 
H. influenzae; 44 – 64 (Genbank accession no. AF076035). 
M. catarrhalis; 39 – 59 with one mismatch at base 6 (Genbank accession no. 
AF192341). 
S. pneumoniae; 19 – 35 (only partial alignment with the 16S sequence (Genbank 
accession number - GU326247). 
A. otitidis; 21 – 38 with a mismatch in base 7 of the primer (Genbank accession 
number - AY957475). Note that the BLAST database lists A. otitidis as A. otitis. 
C. auris; 15 bases of the 21 base primer bind between 9 – 23 at 100% identity 
(Genbank accession number - NR_026211).  
T. otitidis; 20 – 34 (15 bases of the 21 base pair primer matches the T. otitidis 16S 
gene). (Genbank accession number - NR_026120). 
 COM2R binding position in the 16S sequence of studied species 2.10.1.2
(listed as 3’ to 5’ of genomic sequence): 
H. influenzae; 885–866 (one mismatch; Genbank accession number - HQ846514). 
M. catarrhalis; 881–862 (one mismatch at 871; Genbank accession number-
AF005185). 
S. pneumoniae; 904 – 885 (Genbank accession number - GU326247) 
A. otitidis; 909 – 890 (Genbank accession number - AY957475) 
T. otitidis; 902 – 883 (Genbank accession number - NR_026120) 
C. auris; 867 – 848 (Genbank accession number - NR_026211) 
 Second round primers 2.10.2
 702R binding positions 2.10.2.1
702R binds in the following positions of the six bacteria of interest: 
676 to 696 in A. otitidis sequence (EMBL accession no. 59765), 679 to 699 in H. 
influenzae sequence (GenBank accession no. M35019), positions 630 to 650 in 
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the M. catarrhalis sequence (GenBank accession no. L13736), and positions 567 
to 587 in the S. pneumoniae sequence (GenBank accession no. X58312) 
(Hendolin et al. 1997), 702 and 682 Corynebacterium spp. (Genbank accession no. 
AY259129.1), and 696 and 679 in an uncultured Turicella spp. (with one 
mismatch at 689; Genbank accession no. AY494657.1). 
 Second round species specific forward primers  2.10.2.2
Binding positions of the species specific forward primers (accession numbers 
given for the primers designed by this study): 
AO primer 437 to 456; CA primer 133 – 150 (NCBI ref seq: NR_026211.1); TO 
primer 138 – 155 (NCBI ref seq: NR_026120.1); HI primer - 177 to 200; MS 
primer - 416 to 435; SP primer - 106 to 127. 
Specific primers give the following product sizes when used with the 702R 
reverse primer:  
HI;525, SP;484, AO;264, MS;237, CA;569, TO;564. 
2.11 Multiplex PCR 
In an attempt to optimize a multiplex reaction, the primer concentrations stated in 
Hendolin et al (1997) were used with the four specific forward primers, as well as 
the 702R reverse primer (Hendolin et al. 1997). Concentrations were as follows: 
AO- 1.6µM, HI- 1.4µM, MS- 0.2µM, and SP- 0.04µM. 702R reverse primer was 
added at a concentration of 0.4µM. Reactions were completed in 0.2mL thin 
walled PCR tubes (Axygen) using Genscript PCR premix 2X (in a 1:1 ratio of 
PCR grade water) which contained all reagents for the reaction, including “Hot 
Start” Script DNA polymerase which requires a 15 minute 95°C activation step. 
PCR parameters were as follows: 95°C for 15 minutes, Followed by 38 cycles of: 
95°C for 30 seconds, 66°C for 45 seconds and 72°C for 1 minute. A final 
extension step of 72°C for 5 minutes ended the reaction. 
Products were identified and visualised using agarose gel electrophoresis as 
described in section 2.6. In confirming the multiplex PCR results, PCR products 
were isolated for sequencing. This used a Zymoclean
TM
 Gel DNA Recovery Kit 
(Zymo Research) to isolate the differently sized bands separately. PEG and rAPid 
Alkaline Phosphatase protocols could not be used with the multiplex protocol, as 
more than one PCR product was present in the reaction vessel. 
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2.12 Nested PCR optimization 
This nested PCR protocol involves the amplification of universal 16S DNA in an 
initial round of cycling, followed by species specific DNA amplification in a 
second amplification cycle. 
 First round primer concentration optimisation 2.12.1
Variations of first round primer concentrations were tested to determine which 
yielded optimum results. Final concentrations chosen were 0.125µM of COM2R 
and 0.05µM of 63f. 
 Gradient PCR 2.12.2
PCR parameters for both the gradients described in the following sections were as 
follows: 95°C for 3 minutes, followed by 30 cycles of; 95°C for 20 seconds, either 
50°C to 60°C or 54°C to 66°C for 20 seconds, then 72°C for 30 seconds. Reaction 
ended on a 72°C extension step for 5 minutes. 
 First round annealing temperature optimization 2.12.2.1
A gradient PCR was used to determine the best annealing temperature for the first 
round primers 63f and COM2R. This utilised Staphylococcus aureus DNA and 
used a Peltier thermal cycler (PTC-200). Temperatures 50°C to 60°C were tested. 
This gradient also determined amplification efficiency at two different DNA 
concentrations (600ng/20µL and 50ng/20µL).  
The reaction mixture used included 1X Buffer B (Solis Biodyne), 0.5U of 
FIREpol DNA Polymerase (Solis Biodyne) per 20µL reaction, 2mM MgCl2, and 
250µM of each dNTP (A, G, C and T, Solis Biodyne). Note that this is not the 
reaction mix subsequently chosen for first round use. 
55°C was the annealing temperature chosen for use in the first round. 
 Second round annealing temperature optimisation 2.12.2.2
Hendolin et al (1997) used the annealing temperature of 66°C for their four 
specific primers AO, SP, HI, and MS (Hendolin et al. 1997). TO was observed to 
anneal at this temperature, however CA did not. Using 702R as the reverse primer, 
a gradient of annealing temperatures between 54°C and 66°C was run on a Peltier 
thermal cycler (PTC-200). Reaction mix was the same as used in the first gradient. 
This led to the use of 61°C as the second round annealing temperature. 
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 First round reagents and PCR parameters: 2.12.3
Both first and second round amplification cycles were completed on a Bioer 
LifePro Thermal cycler (Model number: TC-96/G/H(b)A) using SnapStrip* 8 
strip 0.2mL PCR tubes (Scientific Specialties Inc.). 
After initially using the same reaction mix as the second round of amplification, 
the first round reaction mix was changed to: 1:1 ratio of 2X GoTaq Hot Start 
Green Master Mix (Promega) to MQ-H2O (Barnstead), 0.1µM of COM2R and 
0.05µM of 63f.  
First round parameters were as follows: 3 minutes at 95°C, 25 cycles of; 20 
seconds at 95°C, 20 seconds at 55°C, and 45 seconds at 72°C. Then a final 
extension step of 72°C for 5 minutes. 
 Second round reagents and PCR parameters; 2.12.4
1µL of the first round products (taken straight from the PCR vessel) were added to 
the following reagents; 
1X Buffer B (Solis Biodyne), 0.5U per 20µL reaction of Hot FIREpol (Solis 
Biodyne), 2mM MgCl2, and 250µM of each dNTP (A, G, C and T, Solis Biodyne). 
Respective forward primers and the reverse primer were used at a concentration of 
0.4µM. 
A touchdown PCR was utilised for increased specificity in the second round of 
PCR. Parameters were as follows: 
15 minutes at 95°C followed by; 
8 cycles of; 20 seconds at 95°C, 20 seconds at 68°C to 61°C (with temperature 
decreasing 1°C per cycle), 30 seconds at 72°C. 
Then 22 cycles of; 20 seconds at 95°C, 20 seconds at 61°C, 30 seconds at 72°C. 
Cycling ends with a 5 minute extension step (72°C).  
To ensure amplification accuracy, a subset of second round products were isolated 
for sequencing and sent for sequencing. These products were isolated using the 
rAPid Alkaline Phosphatase purification method, followed by gel quantification. 
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2.13 Statistical analysis 
A chi-squared test was used to determine the statistical significance of in 
colonisation between OM study group and the OM-free control group.  
The lack of independence between the left ear canal and the right ear canal 
complicated statistical analysis. Each patient has one NP and two OEs. A simple 
chi-squared test could not be used to compare the OEs with the colonisation 
results in the NP as these three orifices are not completely independent of each 
other. Therefore, a McNemar‟s test which takes into account the lack of 
independence was used to determine statistical significance in colonisation 
between the OE and NP. 
2.14 Sau-PCR: genetic fingerprinting of polymicrobial 
populations. 
Sau-PCR creates a distinct banding pattern or „fingerprint‟ which differs between 
isolated organisms and can be used to compare between mixed populations. This 
can be used as a crude method to determine species diversity in an unknown 
bacterial population or could be useful in comparing a known species banding 
pattern with those of unknown species/mixed population, in an attempt to identify 
whether that bacteria is present in the sample.  
This fingerprint is created by the digestion of genomic DNA using the Sau3AI 
restriction enzyme, which cuts DNA at specific sites leaving sticky ends (Corich 
et al. 2005). Specific primers based on the restriction enzymes recognition 
sequence then amplify the fragmented DNA, creating a fingerprint based on the 
genomic sequence. This fingerprint will differ depending on the number of 
recognition sites in an isolated species, or in a mixed population of species 
(Corich et al. 2005).  
The Sau-PCR procedure is as follows: 
Digestion: 
10µL of DNA solution (200ng total) was digested at 37°C overnight with 10 units 
of Sau3AI or MboI (2µL). The reaction mix contained the appropriate restriction 
buffer (2µL of 10X NE Buffer 1 + bovine serum albumin (BSA) or NE Buffer 4) 
in a final volume of 20µL (made up with 6µL MilliQ H2O). After incubation was 
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complete, the temperature was raised to 65°C for 20 minutes, in order to 
deactivate the restriction enzyme.  
Amplification cycles: 
The Sau-PCR was completed in a reaction volume of 25µL in 0.2mL 
microcentrifuge tubes (eppendorf) using a Peltier Thermal Cycler. Reagent 
concentrations were as follows; 2µL of Sau3AI or MboI-digested DNA (10 
ng/µL), 200µM deoxynucleoside triphosphates, 10mM Tris-HCl (pH 9.0), 50mM 
KCl, 1.5mM MgCl2, 0.5 U Taq polymerase (Hot FIREpol, Solis Biodyne), 2µM 
primer (Corich et al. 2005). Primers used are listed in Table 2.2 (Corich et al., 
2005). SauC was the most regularly used. 
Table 2.2 Length, sequence and annealing temperature of Sau-PCR primers.  
(Corich et al, 2005). 
 
Sau-PCR parameters were adapted from the paper by Corich et al (2005) with one 
major difference in the initial activation step, as we used Hot FIREpol DNA 
polymerase (Corich et al. 2005). PCR parameters are as follows: 
95°C for 15 minutes; 
DNA was then added before; 
25°C for 0:05 seconds; 
Increase in temperature by 0.1°C/s until 60°C is reached; 
60°C for 0:30 seconds. 
The following is cycled through twice: 
95°C for 1 minute; 
50°C for 0:15 seconds; 
Primer Length (nt) Sequence 5' to 3' Annealing T (°C)
SauA 12 CCGCCGCGATCA 44
SauC 12 CCGCCGCGATCC 46
SauG 12 CCGCCGCGATCG 46
SauT 12 CCGCCGCGATCT 44
SAG 13 CCGCCGCGATCAG 48
SCA 13 CCGCCGCGATCCA 48
STG 13 CCGCCGCGATCTG 48
SGAG 14 CCGCCGCGATCGAG 52
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Decrease in temperature by 0.1°C/s to 25°C; 
Increase in temperature by 0.1°C/s to 50°C; 
50°C for 0:30 seconds. 
The following is cycled through 39 times; 
95°C for 0:15 seconds, 48°C for 1:00, 65°C for 2:00 minutes. 
Reaction is ended with a 65°C extension step for 5 minutes. 
Cloning of the Sau-PCR products was attempted using DNA acquired from band 
stabbing 2% agarose gels stained with RedSafe. 
2.15 Sequencing reactions 
Samples of interest were sequenced at the Waikato DNA Sequencing Facility. 
DNA sequences were resolved using a 3130xl Genetic Analyzer System fitted 
with 50 cm capillary arrays (Applied Biosystems) loaded with POP-7 
polyacrylamide matrix (Applied Biosystems). DNA templates were prepared 
using Big Dye v3.1 terminator chemistry (Applied Biosystems). 
 
           Chapter 3: Results 
39 
 
3 Chapter 3: Results 
3.1 Study participants 
Full patient information can be found in Appendix II. Basic statistics on the age, 
gender, ethnicity, and PCV7 vaccine dosage are listed in Table 3.1 (control group) 
and Table 3.2 (OM patient group). One control participant‟s bacterial results were 
excluded from the study due to a history of OM (Patient #1C). 
Controls were on average 2 month older than OM patients. A total of 54 males 
and 24 females participated in the study. The control group demonstrated more 
variation in ethnicity than the OM group, however Maori and New Zealand 
Europeans dominated both. Overall, 23 Maori, 46 New Zealand Europeans, and 9 
other ethnicities participated in the study. The variation in bacterial prevalence 
between the ethnicities was not determined. 
Table 3.1 Basic information of the control study group involved in this study. 
 
Average age: 3yrs 7mnths
Gender: M 27
F: 9
Ethnicities:
Maori 11
NZ European 16
European 3
Maori-Polynesian 1
Other European 1
Polynesian 1
Indian 1
Cook Island Maori 1
Somalian 1
PCV7 dose number:
1 0
2 0
3 2
4 14
0 20
Control patients
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Table 3.2 Basic information on the otitis media patient group involved in this 
study. 
 
3.2 Culture 
 Culture analysis 3.2.1
Culture results are a snap shot of the bacteria that were present, and culture viable 
using particular conditions, during sample collection. In this research, culture was 
used to determine the bacterial prevalence in New Zealand children beyond the 
six bacteria of interest.  
Direct DNA extraction from swabs, as well as culture analysis was unable to be 
undertaken on the same samples. This is because the streaking of the swab onto 
culture plates removes many microorganisms that would subsequently be lysed in 
the direct DNA isolating technique, decreasing the amount of DNA obtained for 
non-culture analysis. MEE samples can however be used in more than one type of 
analysis, as only 100µL is used in direct DNA extraction. Therefore 5 MEEs were 
analysed by both direct extraction and culture. 
Further problems with culture analysis include: 
 A lack of antibiotic profiles. As such, the use of unknown antibiotics 
could introduce bias into culture analysis.  
Average age: 3yrs 5mnths
Gender: M 27
F: 15
Ethnicities:
Maori 12
NZ European 30
OM Diagnosis:
Unknown 4
OME 24
RAOM 13
AOM 1
PCV7 dose number:
1 1
2 0
3 1
4 13
0 27
OM patients
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 Selective media is not available that grows all six bacteria of interest 
equally.  
Therefore, culture analysis was only completed on a small subset of samples.  
DNA from mixed culture was not used with the nested PCR protocol. The reason 
behind this can be seen when looking at the results using DNA extracted from the 
non-selective media, BHI+FCS broth (Figure 3.1). Increased background and non-
specific activity made positive and negative results unclear. Due to this difficulty 
in interpretation, sequencing of the 16S or gyrB gene was used to identify more 
exactly the isolated species from culture samples, beyond those of the species of 
interest.  
 
Figure 3.1 The results using the nested PCR protocol on DNA isolated from 
BHI+FCS non-selective broth. Though clear positives are present, a number 
of non-specific bands are visible, complicating results interpretation. 
Contamination issues with the 16S universal primers required the introduction of 
the Shrimp DNAse recombinant step before amplification. Further, the use of 
gyrB primers was abandoned early due to the lack of sequencing information on 
this gene in BLAST for sequence comparisons.  
 Culture results 3.2.2
Of 42 OM patients; 11 OE, 7 NP, and 8 MEE samples were analysed using 
culture. Further, of the 36 control patients 4 OE and 2 NP samples were analysed. 
10% blood agar and 10% chocolate agar were used as the culture medium. 
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Species cultured in BHI+FCS were not identified (as detailed in section 3.2.1), 
however some of these samples were used with the Sau-PCR protocol (see section 
3.12). Extended BLAST results and a subset of electropherogram data from the 
sequenced organisms can be found in Appendix V, Section 1.  
Basic information on the cultured organisms can be found in Table 3.3. Species 
noted on this table are not a 100% confirmation of their presence, as many 16S 
sequences of the same genus are very similar. For example, sample 25CNP-C was 
initially identified as M. nonliquefaciens. However, the same degree of alignment 
can be found with M. catarrhalis. Electropherogram results account for a number 
of the discrepancies seen in the sequence comparisons, as well as the low e score 
of a small number of samples (see Appendix V). 
Not all of the organisms that were cultured were also sequenced. There are many 
reasons behind this, which include; early cultured organisms were used in an 
attempt to optimise protocols that were eventually abandoned, the DNA was 
unable to be successfully extracted (or amplified in some cases), and in some 
cases only the most dominant species on the plate were isolated. Further, a 
number of samples were culture negative. For example, of the eight cultured MEE 
samples, three yielded no bacterial growth after an extended period of incubation. 
The inability to align the sequence of 26CNP-B further than its genus to 
sequences in the BLAST database demonstrates the complexity of the microbiome 
of this site. Reanalysis of this DNA sequence in years, or even months to come, 
may lead to a species level identification. A similar problem was found in the use 
of the gyrB sequences from the 1NP organisms.  
Initial identification of the cultured isolates from 1NP (now identified as S. oralis 
and S. salivarius) using the sequence of their gyrB gene proved unsuccessful, as 
no alignments were found in the BLAST database. However, re-examination 
some months later allowed identification, as the genome of these organisms had 
been sequenced in the meantime. The HMP and other organisations are currently 
sequencing and making available the complete genomes of human colonising 
bacteria. This means that in future research, this gene could prove to be a useful 
tool for analysis. 
 
  
 
4
3
 
Table 3.3 Information obtained from the sequencing of cultured isolates. Table includes information on sequencing primer, most likely species, 
the number of bases run through BLAST, gaps present and the percentage the sequence aligned with the database sequence.  
 
Sample Organism ID gene Primers Sequencing primer BLAST Identification Bases compared Gaps Identifies
1RE A gyrb gyrase b f/r gyraseb reverse Staphylococcus epidermidis 129 0 100%
8RE A 16S AO/COM2R 702R Alloiococcus otitidis 171 0 100%
3LE A 16S 63f/DG74 1195R Alloiococcus otitidis 432 0 100%
6LE A 16S AO/COM2R 702R Alloiococcus otitidis 130 0 100%
1NP A gyrb gyrase b f/r gyraseb reverse Streptococcus oralis 160 0 96%
1NP B gyrb gyrase b f/r gyraseb reverse Streptococcus salivarius 74 0 92%
2NP A 16S MS/COM2R 702R Moraxella catarrhalis 166 0 100%
3NP A 16S TO/COM2R 702R Turicella otitidis 378 0 100%
26NP A 16S 63f/DG74 1195R Uncultured Dolosigranulum 433 1 99%
9LM A 16S 63f/DG74 1195R Alloiococcus otitidis 349 0 100%
26RM A 16S 63f/DG74 1195R Staphylococcus species 466 0 99%
29RM A 16S 63f/DG74 1195R Staphylococcus aureus/haemolyticus 292 0 100%
25CLE A 16S 63f/DG74 1195R Staphylococcus auricularis 220 2 95%
25CRE A 16S 63f/DG74 1195R Staphylococcus auricularis 304 1 99%
25CRE B 16S 63f/DG74 1195R Staphylococcus epidermidis 240 2 99%
26CLE A 16S 63f/DG74 1195R Alloiococcus otitidis 240 3 98%
26CRE A 16S 63f/DG74 1195R Alloiococcus otitidis 180 7 96%
25CNP A 16S 63f/DG74 1195R Corynebacterium pseudodiphtheriticum 271 0 99%
25CNP B 16S 63f/DG74 1195R Dolosigranulum pigrum 263 5 98%
25CNP C 16S 63f/DG74 1195R Moraxella catarrhalis 320 0 99%
26CNP A 16S 63f/DG74 1195R Dolosigranulum pigrum 405 0 99%
26CNP B 16s 63f/DG74 1195R Uncultured bacterium clone 343 0 100%
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As previously stated, the 16S sequence of M. catarrhalis and M. nonliquefaciens 
are very similar. The sequences isolated from the organisms under the labels 2NP-
A and 25CNP-C, when aligned with the BLAST database, were initially identified 
as M. nonliquefaciens. Recognition of their alignment with M. catarrhalis only 
occurred when the Moraxella taxid was selected for in the search parameters. 
Gram stain results indicated that both organisms were gram negative diplococcus. 
This is consistent with M. catarrhalis, as M. nonliquefaciens is rod shaped. This 
provided definitive evidence of their true species identity. 
The plates culturing the NP samples were more densely populated than those of 
the OE samples. This demonstrates the more extensive colonisation of this area. 
Slower growing organisms, like A. otitidis which was observed to take a minimum 
of four days to grow, may have therefore been undetectable due to faster growing 
organisms of the sampled sites. OE samples were not as regularly densely 
populated, possibly allowing time for A. otitidis to grow without being overrun by 
other species. 
Of the six species targeted by the second step of nested PCR, only A. otitidis, T. 
otitidis and M. catarrhalis were cultured. This is not surprising as S. pneumoniae 
is a very fragile bacterium, and has a tendency to autolyse when grown to 
stationary phase (Saha et al. 2011). H. influenzae is also sensitive to 
environmental stresses, such as those endured during storage of the samples. C. 
auris is less prevalent than A. otitidis, but is also slow growing, and therefore may 
have been overcome by other fast growing organisms if it were present in the 
sample. 
Considering the low number of samples cultured, the amount of samples positive 
for A. otitidis may suggest that the antibiotics used on OM patients are ineffective 
against this species. However, without full antibiotic prescription reports, 
antibiotic susceptibility profiles, and further culture data, this hypothesis cannot 
be substantiated. Further, low sample numbers decreases the strength any p values 
this data set may produce. Therefore statistical significance calculations between 
the six species of interest isolated through culture vs. non-culture techniques were 
not completed. 
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3.3 Bacterial DNA Isolation 
Of the 42 OM patients involved in this study, bacterial genomic DNA was 
isolated directly from 67 OE swabs, 43 MEEs and 33 NP swabs. MEE samples 
were unable to be collected in every OM patient because prior to the surgical 
procedure, the child is anesthetized using a gas. The gases ventilate the middle ear 
and can displace previously present exudates, therefore making collection 
impossible (T. Cecire, personal communication, January 13
th
, 2012). Of 36 
control patients, 32 NP swabs and 64 OE samples were directly extracted.  
After extraction, DNA was re-suspended in 20µL of TE before 2µL was used for 
DNA quantification analysis using a ND-1000 spectrophotometer (Nanodrop). 
Table 3.4 depicts the typical spread of Nanodrop results for OM patients, while 
Table 3.5 is an example of those from control participants. DNA concentration is 
given in ng/µL.  
The spectrophotometer measures the absorption of the sample at 230nm, 260nm, 
and 280nm. The 260/230 absorption ratio depicts the levels of nucleic acids to 
phenol in the sample. Pure DNA samples should have a 260/230 ratio of 1.8. 
Purity of the DNA sample is determined by the ratio of absorption at 260nm and 
280nm. A 260/280 ratio of 1.8 – 2 is optimal for minimal non-DNA 
contamination.  
In comparison to the NP, the biomass of OE microbiota is much less. Potentially 
because of this, the purity ratios in the OE samples were not optimal. Further, 
samples may also contain human DNA. All samples were analysed however, and 
PCR results obtained. This suggests non-DNA contaminants predominantly did 
not inhibit cycling reactions, but DNA may have contained undetectable levels of 
some species and were therefore recorded as negative. 
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Table 3.4 Nanodrop results for a subset of OM patients. 
 
Table 3.5 Nanodrop results for a subset of control patients. 
 
Sample ID ng/µL A260 260/230 260/280
33LE 107.68 2.154 0.76 1.50
33RE 95.53 1.911 0.61 1.62
15RE 40.32 0.806 0.61 1.55
15LE 78.75 1.575 0.64 1.45
32LE 102.01 2.040 0.60 1.49
32RE 237.01 4.740 0.62 1.49
32NP 392.57 7.851 1.84 1.82
15NP 115.19 2.304 1.14 1.76
33NP 566.83 11.337 1.55 1.86
21NP 1311.10 26.224 1.05 1.66
24NP 717.18 14.344 1.45 1.81
22NP 812.12 16.242 2.24 1.94
21LM 2689.2 53.785 1.5 1.61
33LM 1926.90 38.538 2.15 1.84
33RM 187.24 3.745 1.24 1.77
32LM 3860.10 77.202 1.37 1.56
18RM 405.26 8.105 1.68 1.78
18LM 1444.10 28.884 1.41 1.76
Sample ID ng/µL A260 260/230 260/280
31CNP 4396.90 87.939 1.80 1.74
29CNP 667.78 13.356 1.66 1.81
24CNP 894.47 17.889 1.39 1.74
19CNP 410.72 8.214 2.06 1.90
20CNP 496.16 9.923 1.85 1.85
1CNP 678.57 13.571 1.76 1.83
2CNP 1001.80 20.037 1.52 1.70
3CNP 2358.20 47.166 1.41 1.73
5CNP 581.75 11.635 1.49 1.76
6CNP 614.67 12.293 1.48 1.79
31CLE 194.31 3.886 0.64 1.46
31CRE 49.84 0.997 0.58 1.57
29CRE 123.47 2.469 0.66 1.39
29CLE 122.00 2.440 0.60 1.49
24CRE 87.84 1.757 0.60 1.46
24CLE 330.69 6.614 0.88 1.61
19CLE 112.08 2.242 0.65 1.42
19CRE 115.50 2.310 0.77 1.44
20CLE 37.25 0.745 0.64 1.45
20CRE 36.97 0.739 0.65 1.39
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A selection of DNA samples were run on a 1% (w/v) agarose gel using TAE 
buffer for 30 minutes at 100V. This was to determine the amount of genomic 
DNA isolated, as the Nanodrop spectrophotometer also measures the rRNA which 
is isolated. Figure 3.2 demonstrates the typical spread of gel results for these DNA 
samples. The OE samples DNA concentration is much less than the other two, to 
the point that it cannot be visualised using gel electrophoresis. Nanodrop 
quantitation results showed DNA was present in the samples, and therefore these 
quantitation results were used. 
 
Figure 3.2 1% (w/v) TAE agarose gel of DNA extracted directly from 
samples. Lanes 1-3 contain MEE samples, 4-6 OE samples, and 7-9 NP 
samples. L = 100bp ladder (Invitrogen).  
3.4 Culture independent extraction efficiency 
The efficiency of the direct DNA extraction technique was assessed by mixing 
cultured organisms of interest on a blood agar plate, running a swab over this mix, 
storing it as we would any other sample, then extracting via the direct swab 
extraction method. The technique did not appear successful with S. pneumoniae 
and H. influenzae and, as often seen in my results from cultured DNA, many non-
specific bands were present (Figure 3.3). T. otitidis and Moraxella spp. negatives 
also both had small amounts of contamination.  
1          2         3        4         5       6           7         8          9        L 
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Figure 3.3  Results using the direct DNA extraction protocol on a swab 
positive for all species of interest, followed by use of the nested PCR protocol, 
visualised on a 1% (w/v) TAE agarose gel. Samples were either negative of all 
bacteria (-), positive using DNA from cultured organisms (+), or positive 
from direct DNA extraction from swab. 
The culture plates that the S. pneumoniae and H. influenzae were taken off had 
both died, due to the fragility of these species in culture. To ensure our procedure 
was able to detect all species, samples that had previously tested positive using the 
direct extraction method were sequenced. Sequencing identified that positive 
results were from the species of interest, and therefore the direct extraction 
procedure had successfully lysed the cells from these bacteria of interest. 
Therefore, use of this extraction procedure went ahead. 
3.5 Multiplex PCR 
Multiplex PCR relies on the specificity of forward primers and the subsequent 
ability to distinguish different sized PCR products, often through gel 
electrophoresis. Initial multiplex attempts, using the primer concentrations stated 
  SP    SP+  SP-    CA   CA+  CA-   MC  MC+ MC-    L 
 HI    HI+   HI-    AO  AO+  AO-   TO    TO+  TO-  L 
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by Hendolin et al (1997) appeared successful, encouraging continuation (Figure 
3.4) (Hendolin et al. 1997).  
 
Figure 3.4 Initial multiplex results. The two bands from the nasopharyngeal 
(NP) sample were isolated separately and sent for sequencing. Sequencing 
results identified the products as H. influenzae (100%), and M. catarrhalis 
(99%), BLAST alignment can be found in Appendix V, section 2). 
Reproduction of these results initially successful results was unable to be achieved 
(Figure 3.5). Nor was the incorporation of the other two primers for bacterium not 
studied by Hendolin et al (1997) successful, despite the separation into two 
multiplex reactions of three primers, then three multiplexes of two primers. 
100bp      NP       AO+ 
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Figure 3.5 Multiplex reactions with single PCR products, despite the 
presence of multiple forward primers. Slight band in the negative. Reactions 
contained the specific primers for, and DNA of: Reaction 1: A. otitidis and S. 
pneumoniae, reaction 2: A. otitidis and H. influenzae, reaction 3: A. otitidis, S. 
pneumoniae, H. influenzae. 
Further complicating issues stem from the CA and TO primers designed using 
primrose technology. These had an overlapping region, leading to their PCR 
products being extremely similar sizes and therefore the inability to use them in 
the same multiplex reaction. These complications and inability to optimise the 
Hendolin et al (1997) protocol led to separation of the reactions. 
3.6 Gradient PCR 
To find the correct temperature for use in the first round of the nested PCR, and 
other reactions using the universal 16S primers, a gradient PCR was run using 
annealing temperatures between 50°C and 60°C. Two different DNA 
concentrations were also tested for efficiency. These concentrations were 30ng/µL 
(600 ng/20µL reaction) and 2.5ng/µL (50 ng/20µL reaction).  
Results showed all reactions at the lower concentration of DNA gave PCR 
products, despite the Tm of COM2R being 50.9°C (Figure 3.6). Of the higher 
DNA concentration reactions, the samples that did not work were at annealing 
temperatures of 52.8°C, 56°C, and 59.8°C. Reactions between these temperatures 
100bp        N                1               2              3 
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did work however, so why these failed is not clear. Looking at these results, 55°C 
was chosen as an appropriate first round annealing temperature.  
 
Figure 3.6 Gradient gel at two different DNA concentrations. 1-6 had 
600ng/20µL of DNA added, while 7 – 12 had 50ng/20µL added. Annealing 
temperatures were as follows: 1 and 7: 50°C, 2 and 8: 50.9°C, 3 and 9: 52.8°C, 
4 and 10: 56°C, 5 and 11: 58.5°C, 6 and 12: 59.8°C. 
Hendolin et al (1997) used the annealing temperature of 66°C for their four 
specific primers for A. otitidis, M. catarrhalis, H. influenzae and S. pneumoniae 
(Hendolin et al. 1997). The TO primer designed for this current study was able to 
sufficiently anneal at this temperature, however the CA primer could not. This led 
to the use of a gradient PCR to determine the highest temperature that CA was 
functional at. 
The CA primer was designed using Primrose technology, and had a Tm of 52.8°C. 
Using 702R as the reverse primer, a gradient between 54°C and 66°C was set up 
to test CA primer functionality. The results are depicted in Figure 3.7. 61°C was 
the temperature that was decided upon for the CA primer. Non-specific activity 
was tested for in the other primers at this temperature, with none found. All 
second round nested PCRs were subsequently completed at an annealing 
temperature of 61°C.  
                 12     11     10     9       8      7       6       5       L 
  4     3      2      1      L 
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Figure 3.7 Gradient gel of C. auris and S. pneumoniae. First six lanes contain 
C. auris primer with C. auris DNA, annealing temperatures stated below 
running lane in °C. Final three lanes contain a positive and negative control 
using SP primer (Tm of 66°C, run at 66°C), and 100bp. 
3.7 Nested PCR 
 Cycling parameters 3.7.1
The correct number of cycles for both the initial universal round and then the 
specific round was investigated. 30 cycles for each round of the nested PCR was 
initially used, resulting in 60 cycles all up. This large number of rounds was used 
to pick up on even the smallest amount of DNA of our species of interest, but led 
to the first round products being visible on a gel after the second round of PCR, 
and non-specific banding (see Figure 3.8). Therefore, the number of first round 
cycles was decreased to 25. With 25 cycles in the first round and 30 cycles in the 
second, many non-specific bands were still seen. These were only removed when 
the number of second round cycles was also decreased to 25 (see Figure 3.9). 
Specificity was further increased by the addition of a touchdown protocol to the 
amplification cycling. 
65.8       64.2        61.2       57.4         55.1          54           SP+        SP-    100bp 
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Figure 3.8 The nested PCR products after 30 rounds of amplification in the 
first and second cycling steps, and with the addition of 100ng/20µL of DNA. 
Smaller products in each reaction correspond to the species specific forward 
primers and 702R amplification. No bands in negatives, but products from 
first round primer 63f and second round reverse primer 702R clearly visible 
(639bp). L: 100bp ladder (Invitrogen).  
 Primer concentrations 3.7.2
Initially, the first round primer concentrations were the same as the concentrations 
used for our second round primers. This meant that often products could be seen 
in the gel after the second, possibly due to first round primer carry over upon 
transfer of first round PCR products to the second round reagents. This led to a 
need for a decrease in first round primer concentration. 
Initial concentrations: 0.4µM of both COM2R and 63f. 
Results of this can be seen in Figure 3.8. 
Final concentrations: 0.1µM of COM2R and 0.05µM of 63f. 
Results of this can be seen in Figure 3.9. 
 DNA concentration added to PCR  3.7.3
Initially, 100ng of DNA was added to the first round reactants. Unfortunately, 
non-specific products, possibly from first round primer carry over, were distin-
guishable under UV visualisation of the EtBr stained gel after the subsequent 
specific cycle. This complicated interpretation of results, and increased the 
likelihood that PCR inhibiting contaminants could influence results (as seen in 
Figure 3.6). This, and results seen in Figure 3.8, led to the decrease in DNA 
addition to 50ng/20µL, which decreased the number of non-specific bands and 
eased interpretation of results (Figure 3.9).  
SP+   SP-    TO+   TO-    CA+   CA-    MC+   MC-   AO+   AO-      L 
~639bp 
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Figure 3.9 Gel of the products from final reagents and parameters of use in 
the nested protocol. There is only one product band after the decrease in 
amplification cycles, first round primer concentrations and amount of DNA 
added. 
 Interpretation of results 3.7.4
The difference between a positive and negative result was subjective. Often there 
were very faint bands which may represent a minute number of these bacteria in 
the sample, background levels of contamination, or residual first round primer 
products. Therefore, only clear positives were recorded as so. As such, negative 
results may be due to the lack of sufficient DNA templates after direct extraction, 
or because the DNA contained PCR inhibiting contaminants. 
 DNA quantification using gel electrophoresis 3.7.5
After a PCR product had been prepared for sequencing through the use of the 
rAPid Alkaline Phosphatase protocol, 5µL of the product was run on a 1% (w/v) 
TAE agarose gel to obtain a crude estimate of the concentration of DNA. Figure 
3.10 is an example of how this was put to use. 
           Chapter 3: Results 
55 
 
 
Figure 3.10 Gel of PCR products that had been subject to the rAPid Alkaline 
Phosphatase protocol. The band closest in size to the PCR products is 
1,500bp’s and 58ng/5µL. Therefore, DNA concentration estimates are as 
follows; 1: 15ng, 2: ~0, 3: 30ng, 4: 30ng, 5: 28ng, all /5µL. 
3.8  Non-culture based results 
Positive results for the bacteria of interest were indicated by the presence of a 
PCR product of correct size after the second specific round of PCR, as visualised 
by gel electrophoresis, and confirmed by the sequencing of a subset of samples. 
Sequencing results can be seen in Appendix V, section 3. Table 3.6 and Figure 
3.11 represent the results derived from all patients in both study groups when 
using the direct swab extraction method and nested PCR protocol. Figure 3.12 
displays results with site and group sampled on the x axis. 
Table 3.6 Prevalence of bacteria of interest in all study participants, 
expressed as a percentage of samples analysed.  
 
Samples Site A. otitidis C. auris T. otitidis Moraxella spp. S. pneumoniae H. influenzae Sample n.
OM NP 9% 12% 6% 70% 24% 48% 33
Control NP 6% 6% 3% 88% 22% 50% 32
OM MEE 16% 9% 21% 44% 9% 51% 43
OM OE 58% 13% 34% 33% 1% 18% 67
Control OE 64% 14% 38% 58% 2% 30% 64
  1         2          3        4          5      100bp 
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Figure 3.11 Bar graph of bacteria of interest with bacterial species on the x 
axis, expressed as a percentage of samples analysed. Differences between 
bacterial colonisation of the studied sites are more substantial than 
differences between study groups. Moraxella spp. prevalence is high across 
all study variables. 
 
Figure 3.12 Bar graph of bacteria of interest with site and group analysed on 
the x axis, expressed as a percentage of samples analysed. The results 
between study groups (eg. NP OM vs. NP Control) are comparable, whereas 
between study sites (eg. NP OM vs. NP OE) many variations can be seen.  
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 Statistical significance between study groups 3.8.1
H0 - There is no difference in colonisation of the six bacterium of interest when 
comparing otitis free controls and otitis media patients. 
Statistical significance between control and OM patient bacterial prevalence was 
calculated using the chi-squared calculation on Statistica software (p values 
presented in Table 3.7). Information on statistical significance calculations can be 
found in Appendix VI.  
Table 3.7 Table of p values when comparing bacterial prevalence between 
study groups, in both the nasopharynx (NP) and outer ear canal (OE). 
Statistical significance was only seen between control and OM patients 
Moraxella spp. colonisation of the OE. 
 
The null hypothesis is rejected only in the case of OE colonisation of Moraxella 
spp.. 
 Statistical significance between body sites studied 3.8.2
H0 - There is no difference in colonisation of the six bacteria of interest between 
the outer ear canal and nasopharynx. 
To compare the NP colonisation with that of the OE (which includes the left ear 
canal and right ear canal), only the patients with all three of those sites analysed 
were included in the analysis. This removed the problem of missing data in the 
statistical significance calculations. A positive result in the OE was counted if one 
or both ears had infection, and a negative if neither had the bacterium. This meant 
only one result was considered for the ear in each patient as is necessary for the 
use of the McNemar‟s test. 30 OM patients and 29 control patients were used in 
this second analysis, the bacterial prevalence in this subset of patients is presented 
in Table 3.8. 
Bacteria NP p value OE p value
A. otitidis 0.6674 0.3903
C. auris 0.4136 0.9167
H. influenzae 0.9028 0.1129
Moraxella spp. 0.0809 0.0023
S. pneumoniae 0.8208 0.974
T. otitidis 0.5728 0.7052
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Table 3.8 Percentages of bacterial prevalence in the NP and OE in a subset of 
participants. Sample n=number of participants included in study 
 
In this subset of participants, some variation can be seen when compared with 
results looking at all participants. These include the complete lack of S. 
pneumoniae in the OE in this subset, the increase in T. otitidis prevalence of the 
OE, the increase in Moraxella spp. in the control OE, but decrease in the OE of 
OM patients, and the increase in C. auris in the OE of both study groups. This 
subset was not used for statistical analysis between study groups as missing data 
was not a factor in those analyses.  
For the analysis comparing the NP and OE colonisation within study groups, the 
McNemar‟s test for statistical significance was used. Appendix VI details how the 
statistical analysis was undertaken. P values are presented in Table 3.9.  
Table 3.9 Statistical significance between the colonisation of each individual 
bacteria when comparing the NP with the OE prevalence. Study groups 
(control and OM patients) were considered separately. Control (CNTL) n=29, 
OM n=30. 
 
The null hypothesis is rejected in the control study group with A. otitidis, C. auris, 
Moraxella spp., and T. otitidis. Rejection of the null hypothesis in the OM group 
occurs with the OE commensals C. auris and T. otitidis. 
The use of NP bacterial prevalence to predict the MEE bacterial profile could not 
be assessed in this research. This is because only 23 OM patients had their MEEs 
analysed, with only 13 of these having both tested. In the NP, only 2, 3, and 2 of 
these 23 patients tested positive for A. otitidis, C. auris, and T. otitidis in one or 
both effusions (respectively). This is not a large enough n to use the McNemar‟s 
A. otitidis C. auris T. otitidis Moraxella spp. S. pneumoniae H. influenzae Sample n
OM NP 10% 13% 3% 73% 27% 47% 30
Control NP 7% 3% 3% 90% 21% 48% 29
OM OE 67% 23% 43% 43% 0% 30% 30
Control OE 66% 21% 59% 69% 0% 48% 29
Bacteria Control OEvsNP p value OM OEvsNP p value
A. otitidis 0.0433 0.0704
C. auris 0.0000 0.0002
T. otitidis 0.0050 0.0004
Moraxella spp. 0.0005 0.3827
S. pneumoniae NA NA
H. influenzae 1.0000 0.1904
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test in determining the true value of NP sampling in pathogen prediction. A larger 
sampling population would be required. 
 Bacteria of interest prevalence results 3.8.3
Using p values to determine statistical significance, and prevalence percentages of 
all the sample sites and study groups, the following results were determined: 
A. otitidis showed no statistically significant differences in colonisation between 
control and OM patients in either the NP (6% and 9% respectively) or the OE (64% 
and 58% respectively). The MEE had a higher prevalence of A. otitidis than the 
NP, but was lower than that of the OE. In the subset of participants, a statistically 
significant difference in A. otitidis colonisation between the NP and OE sites was 
found in the control study group (p=0.0433), but not in the OM group. This 
indicates that OM patients NP and OE are not dissimilar at a statistically 
significant level, despite the 10% vs. 67% colonisation proportion for the NP and 
OE respectively. Because this statistical significance is not present in the OM 
group, the assumption could be made that A. otitidis colonised the NP post-OM, 
as the NP has become accessible to it. This would indicate that A. otitidis 
colonises both areas in a more similar manner in children with OM.  
C. auris colonisation showed no statistically significant difference when 
comparing controls with OM patients in either study site (NP or OE). In the subset 
of participants, colonisation in the control OE (21%) was more substantial than 
that of the control NP (3%), to a statistically significant level (p=0.000). Further, 
colonisation in the OM groups OE (23%) was also statistically significant over the 
NP (13%) (p=0.002). These results would indicate C. auris colonises the OE 
preferentially over the NP in both OM-sufferers and OM-free individuals. 
Substantial colonisation in the MEE by C. auris was not noted. 
The OE was seen to host T. otitidis more frequently than the NP samples in both 
study groups. Using the subset of participants, this difference was statistically 
significant (p=.005, and p=.0004, respectively). Of the three OE bacteria, T. 
otitidis was present in the MEE in the highest number of patients (21%). The 
study groups did not show statistical significance in either body site. A further 
look into the NP shows it is largely absent of T. otitidis, but OM patient NPs did 
have double the prevalence of controls when looking at all participants 
colonisation. 
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Moraxella species showed statistical significance between the colonisation of OM 
patients and controls in the colonisation of the OE (p=.002). This is unusual as it 
was the control OE that had more extensive colonisation than the OE of OM 
patients. M. catarrhalis is a commensal of the NP, and M. nonliquefaciens of the 
upper respiratory tract. How this bacterium got into the control OE in high 
numbers is unknown. No statistical significance was seen between OM patients 
and controls in the NP.  
Colonisation of the MEE by Moraxella spp. was less than that seen in the NP, but 
more than that seen in the OE of OM patients. In the subset of participants, 
statistically significant differences were found between the colonisation pattern of 
the control OE and NP, but not the OM patients. This indicates the OM patient 
colonisation by Moraxella spp. between body sites is more similar than the 
control participants. This may demonstrate the increased propensity for cross over 
in bacterial colonisation of OM patients due to periods of ear drum perforation or 
increased permeability.  
S. pneumoniae was the least prevalent of the three NP pathogens in both study 
groups and all the body sites. In the MEE, S. pneumoniae was less prevalent than 
both A. otitidis and T. otitidis. No statistical significance was found between 
controls and OM patients in the sites analysed. When looking at the subset of 
participants, none were positive for this bacterium in the OE. This led to the 
inability to determine statistical significance using the McNemar‟s test , as no 
results were registered for one of the variables. However, it could be assumed that 
the NP is the preferred site of colonisation. 
H. influenzae did not show statistically significant differences between the study 
groups in either body site. MEE colonisation by H. influenzae was the highest of 
all bacteria analysed, and was in a similar proportion to H. influenzae colonisation 
in the NP of both study groups. Control OE samples tested positive for H. 
influenzae more frequently than those from the OM patients (30% and 18% 
respectively). This difference is unexpected as this bacterium is a commensal of 
the NP, and no known passage between these two areas is known in OM-free 
children. In the participant subset, colonisation of the control OE and NP was the 
same. No statistically significant differences between the studied sites were seen 
in either study group. 
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3.9 The polymicrobial status of studied sites and groups 
within the six bacteria of interest. 
Of the samples that were tested using non-culture techniques and the nested PCR 
protocol, a number were positive for more than one of the six bacteria of interest. 
This is to be expected as OM can be a polymicrobial infection. Table 3.10 details 
the polymicrobial status of the different sample sites and between study groups. 
Overall across all study sites and participant groups, 71 samples were positive for 
only one bacterium, compared to 128 which were positive for two or more. 40 
samples were negative for all studied bacterium. 
Across all study variables, positives for Moraxella spp. alone were regularly 
found. The NP of OM patients was the most regular host site of Moraxella spp., 
while the OM patient OE demonstrated the least. This bacterium was also a 
constituent in the other two polymicrobial populations that dominated the flora of 
OM patients NP. These were the H. influenzae and Moraxella spp. duo, and all 
three NP pathogens together. This last population was also in high proportions of 
control patient NPs, demonstrating the capacity for asymptomatic carriage of 
these three bacteria.  
H. influenzae and Moraxella spp. appear frequently together across all sampling 
variables, predominantly in the NP. However, surprisingly large proportions of 
this duo were found in the OE also. Two interesting points to note are the lack of 
colonisation by S. pneumoniae alone, the only bacteria to fail to do so, and the 
high proportion of H. influenzae only populations in MEEs. 
Of the OE samples, A. otitidis was found alone in high proportion of both study 
groups. Populations of the A. otitidis and T. otitidis duo were found only in the OE 
canal, with OM patients having 3.83 times the frequency of this pair compared to 
controls. This means OM patients are 3.83 times more likely to be colonised by 
these two bacteria together than OM-free controls. A similar increase can be seen 
in the colonisation of the A. otitidis and C. auris duo in OM patients, with a 2.87 
increase in frequency when compared to the control group. Interestingly, control 
participants tended to have these two bacterium plus Moraxella species more 
regularly than just the two OE bacteria. 
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Table 3.10 Percentages of samples that showed either singular, or 
polymicrobial species. Percentages allow comparisons between sites. The 
numbers of samples that were positive for the specified bacteria are 
presented in brackets. Bacterial species have been abbreviated; AO, A. 
otitidis; CA, C. auris; TO, T. otitidis; HI, H. influenzae; MS, Moraxella species; 
SP, S. pneumoniae.  
 
  
MEE OM NP OM NP Control OE OM OE Control
AO 0% 3.03% (1) 0% 14.93% (10) 14.06% (9)
CA 0% 0% 0% 2.99% (2) 0%
TO 2.33% (1) 0% 0% 2.99% (2) 1.56% (1)
HI 20.93% (9) 9.09% (3) 3.13% (1) 1.49% (1) 0%
MS 13.95% (6) 21.21% (7) 28.13% (9) 4.48% (3) 9.37% (6)
AO CA 0% 0% 0% 4.48% (3) 1.56% (1)
AO TO 0% 0% 0% 11.94% (8) 3.12% (2)
AO HI 6.96% (3) 0% 0% 1.49% (1) 0%
AO MS 0% 0% 6.25% (2) 4.48% (3) 12.50% (8)
AO SP 0% 0% 0% 0% 1.56% (1)
CA MS 2.33% (1) 3.03% (1) 0% 0% 0%
CA SP 0% 3.03% (1) 0% 0% 0%
TO HI 0% 0% 0% 0% 1.56% (1)
TO MS 4.65% (2) 0% 0% 0% 3.12% (2)
HI MS 4.65% (2) 15.15% (5) 28.13% (9) 1.49% (1) 7.81% (5)
MS SP 2.33% (1) 6.06% (2) 9.38% (3) 0% 0%
AO CA TO 0% 0% 0% 1.49% (1) 4.69% (3)
AO CA HI 0% 0% 0% 0% 1.56% (1)
AO TO HI 0% 3.03% (1) 0% 1.49% (1) 0%
AO HI MS 2.33% (1) 3.03% (1) 0% 5.97% (4) 4.69% (3)
AO TO MS 0% 0% 0% 7.46% (5) 7.81% (5)
CA TO HI 0% 0% 0% 0% 1.56% (1)
CA HI MS 0% 6.06% (2) 3.13% (1) 0% 0%
CA TO MS 0% 0% 0% 1.49% (1) 0%
TO HI MS 4.65% (2) 0% 0% 1.49% (1) 0%
TO MS SP 0% 3.03% (1) 0% 0% 0%
TO HI SP 2.33% (1) 0% 0% 0% 0%
HI MS SP 2.33% (1) 12.12% (4) 12.50% (4) 1.49% (1) 0%
AO TO HI MS 0% 0% 0% 1.49% (1) 7.81% (5)
AO CA TO MS 0% 0% 0% 1.49% (1) 0%
AO CA TO HI MS 4.65% (2) 0% 0% 1.49% (1) 4.69% (3)
AO CA TO HI MS SP 2.33% (1) 0% 0% 0% 0%
23.26% (10) 12.12% (4) 9.38% (3) 23.88% (16) 10.93% (7)
43 33 32 67 64
Bacterial species present
No positives
Total number of samples
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3.10 Culture vs. non-culture results 
The NP, MEE and OE are known anatomical sites for polymicrobial populations. 
The six bacteria this research has studied are not the be all and end all of 
colonisation of these areas. The culture results further describe the species present 
in these sites (Section 3.2.2). Of the samples analysed by culture, only the MEEs 
were also able to be analysed using non-culture methods. Comparisons between 
these two methods in regards to the MEEs were therefore able to be made. 
3 of the MEE cultures yielded no bacterial growth. The results by PCR of these 
samples agreed in 2 of those cases, but results for the culture negative sample 
from 6RM gave positives in T. otitidis, S. pneumoniae, and H. influenzae using 
non-culture techniques. 29RM, which grew a Staphylococcus spp, was positive 
for 5 of the 6 bacteria of interest using non-culture techniques. This organism had 
grown and taken over the plate overnight, possibly inhibiting these other species 
from growing. 26RM, which was positive for S. epidermidis, yielded positives for 
T. otitidis and M. catarrhalis. This means that these bacterium were present in 
these samples, but failed to culture for any number of reasons.  
The species diversity is further reflected in the complexity of the Sau-PCR 
molecular profiles (see section 3.12). Culture results provide a rough indication of 
the organisms responsible for the banding patterns seen in the Sau-PCR 
fingerprints, as they further demonstrate the complex and polymicrobial nature of 
these sites.  
3.11 S. pneumoniae prevalence and vaccination status 
The PCV7 vaccine history and S. pneumoniae colonisations of participants was 
assessed. Of the 78 children involved in this study, 27 had complete PCV7 
immunizations, 4 had incomplete vaccinations, while 47 were not vaccinated. 
Children with incomplete vaccination profiles were excluded from the analysis.  
2/12 (16%) vaccinated OM patients had S. pneumoniae in their NP (with one of 
these also having it in their MEE), whilst 4/19 (21%) of non-vaccinated OM 
patients were positive for the bacteria (see Table 3.11). This demonstrates a slight 
decrease in the prevalence of S. pneumoniae in vaccinated patients. In addition, 
none of the OEs of vaccinated OM patients were positive for S. pneumoniae, 
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while 2% of non-vaccinated participants tested positive. Contrasting results to 
these were found when looking at the MEE data. 
Table 3.11 PCV7 vaccination status in patients with OM, and the presence or 
absence of S. pneumoniae in the respective body sites. 
  
2/8 (25%) vaccinated OM patients tested positive for this bacterium in their MEE, 
while 2/31 (6%) of non-vaccinated OM patients were positive. This would suggest 
an increased likelihood of S. pneumoniae colonisation in the MEE when 
vaccinated against it, however, the limited number of vaccinated OM patients who 
also had their MEE tested limits these results. More vaccinated participants would 
need to be tested to confirm this. Data on serotype or antibiotic resistance profiles 
were not completed. 
6/13 (46%) vaccinated control patients tested positive for S. pneumoniae in their 
NP. All but one of the control patients who tested positive for S. pneumoniae in 
this site were vaccinated against it (see Table 3.12). This may indicate the 
replacement of S. pneumoniae serotypes in the NP of control patients. Serotypical 
information on the positive results would need to be undertaken to confirm this 
statement. 
OM Patients S. pneumoniae %+ve
OM OE Present Absent Total
Vaccinated 0 21 21 0%
Non-vaccinated 1 41 42 2%
Total 1 62 63
OM NP Present Absent Total
Vaccinated 2 10 12 16%
Non-vaccinated 4 15 19 21%
Total 6 25 31
OM MEE Present Absent Total
Vaccinated 2 6 8 25%
Non-vaccinated 2 29 31 6%
Total 4 35 39
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Table 3.12 PCV7 vaccination status in control participants, and the presence 
or absence of S. pneumoniae in the respective body sites. 
 
The numbers of participants who had been vaccinated were markedly lower than 
those who had not been. This led to a smaller number of results for the vaccinated 
group, possibly limiting the strength of these results. 
3.12 Sau-PCR Microbial Community Assessment 
Genomic DNA was digested with either SauAI3 or MboI restriction enzymes. 
Subsequent amplification cycles with Sau primers yielded banding patterns 
representative of the number of GATC cut sites plus an additional dinucleotide or 
single nucleotide (e.g. SauC primer elongates those with GATCC) present 
throughout the digested bacterial DNA. Comparisons between the fingerprint of 
different samples gives an indication of similarities and/or differences in bacterial 
diversity. SauC and SauA primers were used most extensively. Figure 3.13 
demonstrates the difference between the two primers on the same DNA from 
mixed cultures. The SauC primer yielded a larger number of bands with 
reasonable product yields (as approximated by band brightness) and was therefore 
used the most. 
Control S. pneumoniae
Control OE Present Absent Total %+ve
Vaccinated 1 23 24 4%
Non-vaccinated 0 36 36 0%
Total 1 59 60
Control NP Present Absent
Vaccinated 6 7 13 46%
Non-vaccinated 1 16 17 5%
Total 7 23 31
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Figure 3.13 Banding patterns from Sau-PCR using both SauA and SauC 
primers. DNA used was from cultured organisms of both NP and OE samples 
from OM patients. L = 100 base pair ladder (Invitrogen). Yellow arrows 
indicate the bands that are of the same size as those seen in the fingerprint of 
the isolated organisms of interest. 
Isolated cultures of the six species of interest were digested to determine banding 
patterns (see Figure 3.14). Three bands appeared quite regularly throughout these 
profiles. These were approximately 500, 390, and 260 base pairs (bps) in size and 
may represent a stretch of DNA with a large copy number. A. otitidis had a much 
brighter band at 260bps than the other samples, as did C. auris at 390bps. H. 
influenzae had two distinctive large bands at approximately 900bps and 780bps, 
which the others lacked. Similar bands as those mentioned above can be seen in 
the SauC profiles of the cultured samples of 4NP (H. influenzae large bands) and 
3LE (C. auris small band) in Figure 3.13. This may indicate the presence of these 
bacteria in those samples; however this is was not confirmed. 
3LE  3RE  3NP 4NP  2NP  2LE  1RE  3LE 3RE  3NP 4NP 2NP  2LE 1RE    L 
 
SauA     SauC 
 
           Chapter 3: Results 
67 
 
 
Figure 3.14 Sau-PCR of DNA from cultured isolates of bacteria of interest 
using SauC primer. L = 100bp ladder (Invitrogen). 
Fingerprinting profiles of DNA from mixed culture yielded different profiles than 
that of DNA from direct swab extraction of the same site (Figure 3.13 vs. Figure 
3.15). Culture banding profiles appear indicative of a larger amount of DNA from 
fewer culturable organisms (Figure 3.13). DNA from the direct extraction 
procedure is representative of more organisms but with less DNA from each to 
digest (Figure 3.15). Therefore the brightness of the bands (DNA yield) and 
number of bands is decreased. Furthermore, some digested DNA may not be 
amplified to a sufficient level for visualisation. Therefore, samples from culture 
are indicative of a smaller number of species, but have more significant DNA 
amplification. 
In an example of Sau-PCR banding patterns potential use in identifying organisms 
present in mixed samples, the ~260bp band present in the A. otitidis banding 
profile is present in all the OE fingerprints presented in Figure 3.15. This could 
indicate the presence of this bacterium in these samples, and indeed all three of 
these OE samples were positive for A. otitidis using the nested PCR protocol 
(Appendix IV contains the raw data from all participants). Other bacteria had less 
unique profiles, so assumptions on their presence could not be made as easily. 
TO      SP     MC      HI      CA      AO   MIX    L 
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Figure 3.15 Sau-PCR results using SauC primer with DNA extracted directly 
from OM patient swabs of the NP, OE and MEE. Sample order is as follows: 
N, 28LE, 17RE, 4LE, 6RM, 27RM, 21LM, 12NP, 16NP, 14NP, L = 100bp 
ladder (Invitrogen).  
Looking at the direct swab extraction DNA digests in Figure 3.15, fingerprints 
from MEEs resembled each other quite closely, as did samples from the NP. 
Furthermore, the resemblance continued between these two sites, but did not 
extend to the OE fingerprint profile.  
More differences were seen between the Sau-PCR profiles of control patients 
when comparing DNA from the OE and the NP, than were seen between the same 
sites in OM patients (Figure 3.15 vs. Figure 3.16). These differences may be a 
reflection of the antibiotic treatments the OM group had previously been 
administered. However, a complete antibiotic profile would be necessary to 
substantiate this hypothesis. 
            OE                  MEE                   NP             L 
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Figure 3.16 Sau-PCR banding pattern using SauC primer with DNA from 
direct DNA extraction from control samples of the NP and OE. Sample order 
is as follows: 8CNP, 12CNP, 23CNP, 23CLE, 24CLE, 3CLE. L = 100bp 
ladder (Invitrogen). 
Sau-PCR profiles using DNA from direct extraction may have contained human 
DNA in unknown quantities. As such, some of the bands present in the banding 
pattern may be representative of the human participant DNA, and not be 
microbiota related.  
More specific identification of the most prevalent species is theoretically possible 
through cloning of the DNA products of the highest yield, however was not 
achieved in this study. The inability to clone the Sau-PCR products meant 
attempts to quickly and efficiently identify dominant species in the sample was 
unable to be completed.  
Specific highly sequenced genes with a large number of alignments in public 
databases (such as 16S) were not selected for before the Sau-PCR digest. This 
whole genome approach provided more information when comparing the 
fingerprints of the organisms. However, the brightest bands may have been from a 
DNA sequence not yet covered extensively in databases such as BLAST. This is a 
possibility for why no matches were found for the cloned DNA sequence. 
N                 NP                         OE                L 
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4 Chapter 4: Discussion 
4.1 Previous findings on bacterial prevalence (culture 
and non-culture techniques) 
The prevalence of A. otitidis and the three NP pathogens has been documented in 
OM patients. One study looked at the prevalence of H. influenzae, S. pneumoniae, 
A. otitidis, and M. catarrhalis in the NP and MEE of OME patients who were 
undergoing ventilation tube insertion (Takada et al. 2003). Table 4.1 demonstrates 
their results when using both culture and non-culture based techniques. A. otitidis 
failed to culture, however was detected in 28.9% of MEEs and 10.7% of NP 
specimens using non-culture techniques. This reinforces the use of culture-
independent techniques when studying slow growing organisms, such as A. 
otitidis, T. otitidis, and C. auris. 
Table 4.1 Table of prevalence of bacteria expressed as a percentage of total 
samples (Takada et al. 2003). 
 
It is interesting to note that the proportion of positives for A. otitidis in the MEE is 
higher than those positive in the NP. This would indicate that the source of A. 
otitidis for these infections would be elsewhere (Takada et al. 2003). M. 
catarrhalis was the most prevalent bacteria in the NP; however had the least 
prevalence in the MEE.  
Other studies have also found A. otitidis in high proportions of MEEs. Guvenc et 
al (2010) used culture techniques and found A. otitidis more frequently than other 
major nasopharyngeal pathogens in MEEs (Guvenc et al. 2010). Another study 
cultured A. otitidis from 48.27% of MEEs, providing further evidence that this 
bacterium is present in the middle ear cavity during episodes of OM (Martinez & 
Macias 2008). Both studies looked at patients with a more chronic form of 
infection (OME), which A. otitidis has been suggested to play more of a role in 
(Leskinen et al. 2002). 
Bacteria MEE % NP %
S. pneumoniae 4.8% 8.9%
H. influenzae 7.2% 12.0%
M. catarrhalis 3.6% 30.4%
A. otitidis 28.9% 10.7%
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Harimaya et al (2006) looked at the prevalence of A. otitidis using culture-
independent techniques, and compared study groups of otitis-prone and non-otitis-
prone children (all participants were OM sufferers) (Harimaya et al. 2006). Of the 
MEE samples from non-otitis-prone children, 13.8% were positive for A. otitidis, 
while 64% of otitis prone children were positive. This difference in colonisation 
showed statistical significance (p<0.001). In addition, A. otitidis was found in 
higher proportions of NP specimens from the otitis prone children (29.4%) when 
compared to non-otitis prone (2.6%). This difference also showed statistical 
significance (p<0.001). Results such as these further provide evidence for the 
potential role of A. otitidis in the chronicity of OM. 
Looking at the differences between OM-free controls and OM patients, the 
colonisation of the NP and MEE of Turkish children has been compared (Eser et 
al. 2009). A 2-fold increase was found when looking at the NP colonisation of S. 
pneumoniae and H. influenzae between the two study groups. This difference was 
not found to be statistically significant. Furthermore, the presence of bacterial 
pathogens in the NP was not indicative of the pathogens presence in the child‟s 
MEE (Eser et al. 2009). 
Looking at healthy individuals, the prevalence of bacterial species in 70 
volunteers between the ages of 19 and 22 has been assessed using culture 
independent techniques (De Baere et al. 2009). Nasopharyngeal pathogens were 
found in the NP at a rate of 14% for H. influenzae, 34% for M. catarrhalis and 9% 
for S. pneumoniae. This study reports that A. otitidis was completely absent from 
the NP, while OE positives for this bacterium were detected in 83% of samples.  
C. auris and T. otitidis were not targeted in the non-culture techniques of this past 
study. However, in a cultured subset of 10 OE samples, 5 grew T. otitidis, while 2 
grew C. auris (De Baere et al. 2009). 9 of the 10 cultured samples grew ≥2 species, 
with the one exception being a pure culture of A. otitidis. This further cements the 
polymicrobial status of these anatomical sites. 
In addition, culture independent research has found no NP pathogens in the OE of 
24 healthy individuals (predominantly adults) (Frank et al. 2003). This disagrees 
with the study by De Baere et al (2009) who report a carriage rate in the OE of 6% 
for H. influenzae (De Baere et al. 2009). As previously referred to in the 
introductory sections, Frank et al (2003) found the OE commensal bacteria A. 
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otitidis, T. otitidis, S. auricularis, and C. auris to be the four most prevalent 
species of the OE (Frank et al. 2003). 
Comparisons between culture and PCR based results demonstrate the increased 
sensitivity of the latter. Evidence provided by De Baere et al (2009) showed that 
out of 10 samples, 9 tested positive by PCR for A. otitidis, while only 5 of these 
were positive when using culture (De Baere et al. 2009). Further use of culture 
techniques have shown T. otitidis and C. auris to be the two most prevalent 
coryneforms from the OE and the cerumen of healthy adults, with A. otitidis the 
third most prevalent bacteria overall (Stroman et al. 2001). Due to the high 
frequency of positives, these authors considered this to demonstrate that these 
bacteria are part of the normal OE flora. 
Organisms hypothesised to play an „interfering‟ role in the colonisation of OM 
pathogens have been observed using metagenomic non-culture based techniques. 
These bacteria include the genus‟ Corynebacterium and Dolosigranulum who, 
when present, are thought to compete with pathogenic species for colonisation, 
possibly leading to a decrease in OM frequency (Laufer et al. 2011). 
Looking specifically at T. otitidis colonisation in OM sufferers, 153 MEEs from 
112 patients were cultured and assessed for presence of this bacterium. 9 exudates 
tested positive from 7 different patients (Gomez-Garces et al. 2004). 5 of these 
were isolated from patients who had a well-documented history of infection, and 
predominantly had a visible perforation of the ear drum.  
Other bacteria isolated in this past study include all three of the known OM 
pathogens studied here (proportions not published), S. aureus, Pseudomonas 
aeruginosa and enterobacteria (Gomez-Garces et al. 2004). In addition, cultured 
bacteria from a recent study found commensal bacteria of the skin Staphylococcus 
auricularis and Staphylococcus epidermidis in the NP of sufferers of Chronic 
Suppurative OM (CSOM) (Chang et al. 2011). 
Earlier investigations into the bacterial prevalence in New Zealand children with 
OME include the study of a group of Auckland children in the 1990s using culture 
techniques on 105 MEEs (67 patients) (Watson et al. 1996). Specifically looking 
at nasopharyngeal pathogens, H. influenzae was found in 16% of MEEs, S. 
pneumoniae in 8%, and M. catarrhalis in 12% (Watson et al. 1996).  
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Further research in New Zealand looking at four of the bacteria of interest found 
the following percentages of positives in 98 MEE samples: 81% for A. otitidis, 35% 
for S. pneumoniae, 18% for H. influenzae, and 27.5% for M. catarrhalis (Cecire et 
al. 2009). This New Zealand study went further to explain the polymicrobial 
nature of OM infections (Cecire et al. 2009). Of the 98 participants, 41% tested 
positive for one of the four bacteria they studied, 29% for two, 16% for three and 
4% for all four. The majority therefore were positive for more than one species.  
4.2 Comparisons with results of this study 
 Cultured species 4.2.1
The cultured species of this present study have previously been associated with 
the studied sites (Bogaert et al. 2011). Both Dolosigranulum pigrum and 
Corynebacterium pseudodiphtheriticum have been found in the URT of children 
suffering from an URTI. Results from this current study found D. pigrum in both 
of the control NP samples that underwent culture analysis, and C. pseudodiphther-
iticum in one of these. Only one of the NP samples from OM patients tested 
positive for Dolosigranulum spp.. Laufer et al (2011) linked the colonisation of 
these bacteria to a decreased risk in developing OM (Laufer et al. 2011). Low 
numbers of cultured samples limit the ability of this current research to provide 
evidence towards this. 
Unlike the study by Takada et al (2003), A. otitidis was the most regularly isolated 
bacterium through culture in this current study (Takada et al. 2003). This 
difference in cultivation could be because of the long incubation period used here, 
however the previous study does not state the length of their incubation for 
comparison. Five OE samples tested positive for this slow growing organism, as 
did one MEE across both the control and OM study groups. No obvious trend 
between colonisation of the study groups was observed in this organism. 
Staphylococcus species were cultured from samples of the OE canal, in both the 
control and the OM patient samples. This is in agreement with the results from a 
2003 study, which found these same bacteria in the OE of healthy adults, 
providing evidence that they are commensals of this anatomical site (Frank et al. 
2003). Further, S. epidermidis and S. auricularis have been noted in the NP of 
sufferers of CSOM (Chang et al. 2011). The evidence put forward by Chang et al 
(2011) may indicate that these Staphylococci become opportunistic pathogens 
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after a primary ear infection (Chang et al. 2011). As none of these species were 
cultured in the NP of OM individuals in this current research, results here cannot 
substantiate this hypothesis.  
This limited number of cultured samples gives us an indication of the bacteria 
found in the study sites beyond those of the six bacteria of interest. Indicating the 
microbial flora of New Zealand children agrees with the flora isolated in varying 
locations worldwide (Bogaert et al. 2011; Laufer et al. 2011). Further research 
using a larger number of cultured samples would provide further information into 
the extended number of species present. Antibiotic susceptibility profiles, which 
can only be conducted on cultured organisms, may further prove useful in 
determining future treatments of OM.  
 Bacterial prevalence 4.2.2
The results of this study show a number of differences to those from a previous 
culture based study (Takada et al. 2003). Despite the larger number of participants 
in the previous study, this difference in results may demonstrate the increased 
efficiency of DNA-based techniques in identifying small populations of non-
culturable species in polymicrobial samples. It could also indicate the possibly for 
differences between global location, as the previous study was conducted in Japan 
(Takada et al. 2003). 
The difference in A. otitidis prevalence between the anatomical sites, in this and 
previous studies, would suggest the bacterium colonises the MEE from the 
population in the OE, rather than the NP (Takada et al. 2003). 16% of MEEs 
tested in this current study were positive for A. otitidis. This is a larger proportion 
than were positive in the NP (9%). The higher prevalence in the MEE could be 
from OE contamination. Although due to the agreement with previous studies, 
this may be a true result (Takada et al. 2003).  
Previously, non-otitis prone children with OM have shown positives for A. otitidis 
in 13.8% of children‟s MEE, a similar result to this study (Harimaya et al. 2006). 
This past study also found A. otitidis in similarly low proportions of OM patient 
NPs, with a statistically significant difference between A. otitidis colonisation in 
otitis-prone and non-otitis prone children (p<0.001). This current study found no 
such correlation between OM patients and OM-free controls as, despite the 
controls almost never having had an episode of OM, a 6% positive rate of 
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colonisation was found in the NP. This disagrees with the results from De Baere 
et al (2010), who found no OE commensal bacteria in the NP of healthy 
individuals (De Baere et al. 2009). 
In comparison to the three NP pathogens, the number of positives for A. otitidis in 
the MEE was only higher than S. pneumoniae. This disagrees with the results seen 
in the study by Guvenc et al (2010) who found A. otitidis in a higher proportion 
than all three of the nasopharyngeal pathogens studied here (Guvenc et al. 2010). 
Furthermore, a previous study found A. otitidis in 48.27% of cultured MEEs from 
Spanish patients suffering from OME (Martinez & Macias 2008). This is much 
higher than the 16% of non-culture based positives this current research found. 
Potential reasons behind this discrepancy include: the potential for global 
differences; the possibility that the DNA extraction technique was not as efficient 
on bacteria present in a mucosal layer/biofilm. 
C. auris colonisation showed no significant difference in colonisation between 
control and OM patients. When looking at all patients, the prevalence appeared to 
be similarly low between all study sites and groups. However, statistically 
significant differences were seen in the subset of participants used to compare the 
OE colonisation with that of the NP. Substantial colonisation in the MEE by C. 
auris did not appear to be present, with 9% of MEE showing positive results. This 
is the same proportion, but not the same patients, as S. pneumoniae.  
At 21%, T. otitidis had the highest prevalence in the MEE of all the OE bacteria. 
This is much more substantial colonisation than that seen in the NP with positive 
results in 3% of control NP, and 6% of OM patients (not statistically significant). 
The OE was seen to host T. otitidis more frequently than the NP, with statistically 
significant differences in between these anatomical sites in both the controls (p= 
0.0050) and OM patients (p=0.0004). With these results, it could be concluded the 
T. otitidis in the MEE originated from the OE and may be an example of this OE 
commensal acting as an opportunistic pathogen during a primary episode of OM. 
T. otitidis was positive in the OE of 38% and 34% of controls and OM patients, 
respectively. Stroman et al (2001), who looked at the bacteria colonising the 
healthy OE of adults, found both T. otitidis and C. auris to colonise at much 
higher proportions than in this current research (Stroman et al. 2001). This 
discrepancy may be due to the older age of the participants in the earlier study, 
and may provide evidence against their pathogenicity. 
     Chapter 4: Discussion 
76 
 
S. pneumoniae has a lowered carriage rate in adults. This is thought to be because 
of an immune response against it (Garcia-Rodriguez & Martinez 2002). T. otitidis 
and C. auris have a higher carriage rate in adults, as seen when comparing the 
results of this study to those of previous research on adults (Stroman et al. 2001). 
This may indicate there is no immune response against colonisation of these 
bacteria, and therefore they may simply be part of the normal flora. At present, no 
research has been published on the immune response against these organisms. 
Further research into this prospect is necessary for substantiation. 
Gomez-Garces et al. (2004) has previously cultured T. otitidis in 9 out of 153 
MEEs (Gomez-Garces et al. 2004). This is a much lower proportion than the 21% 
of positives recorded here. Furthermore, this current research found T. otitidis in 
the MEE more often than A. otitidis. This is unexpected as A. otitidis has been 
known to be the sole bacteria present in high proportions of MEEs, while T. 
otitidis is not (Martinez & Macias 2008).  
De Baere et al (2009) found H. influenzae, A. otitidis, M. catarrhalis, and S. 
pneumoniae in lower proportions in the healthy NP than were found in this 
current research, although the order of prevalence in their results agrees with this 
present study (De Baere et al. 2009). These authors had similar trouble with 
multiplex PCR optimization and therefore also separated their species specific 
reactions. 
M. catarrhalis has previously been recorded as the most prevalent of the three 
nasopharyngeal pathogens in the NP (Takada et al. 2003). The results of this 
current study agree with this notion, showing Moraxella spp. in high proportions 
of NP samples. Further, this study found a high colonisation rate of the NP in both 
OM patients and OM-free controls, indicating just as many children are colonised 
by this bacterium asymptomatically, as symptomatically. 
H. influenzae demonstrated no significant differences when comparing the study 
groups. This is in contrast to the study by Eser et al (2009) which found twice the 
numbers of both H. influenzae and S. pneumoniae in patients with OME than 
infection free controls (not statistically significant) (Eser et al. 2009). Whether 
this is of biological significance remains to be seen.  
H. influenzae was more prevalent in the NP than the OE in both study groups. 
This agrees with the high nasopharyngeal carriage rate of this organism through-
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out the globe (Garcia-Rodriguez & Martinez 2002). Surprisingly, increased 
positives were found in the control group OEs when compared to the OM patient 
OEs, although not to a statistically significant level. Further, Moraxella spp. 
results showed statistically significant differences between the colonisation of 
control and OM patients in the OE (p=0.0023). This was the only difference 
between the control and OM patient groups to reach statistical significance but, 
surprisingly, it was the control OE that demonstrated the larger number of positive.  
These results are highly unexpected as these bacteria are significantly linked to 
episodes of OM, which are absent in the control group. 
Theoretically, an increase in the amount of Moraxella spp. and H. influenzae in 
the OE would be expected in OM patients, as they may experience periods of 
perforation or increased permeability of the ear drum during inflammation. Both 
of which could allow bacteria in the MEE a passage into the OE. This passage 
should be absent in control participants. 
Further, a previous study looking at the OE of healthy volunteers found no NP 
pathogens (Frank et al. 2003), whilst another found H. influenzae in much smaller 
proportions than reported here (De Baere et al. 2009). This discrepancy between 
results could be explained by the older age of the previous studies participants. 
The current research found the majority of healthy OE samples positive for 
Moraxella species, and 30% positive for H. influenzae, which may indicate these 
species are commensal bacteria of the OE as well as the NP. 
Of all six bacteria, H. influenzae gave the most positives in the MEE at 51%. This 
is in contrast to a previous study which found A. otitidis to be the most prevalent 
species of the MEE by culture (Takada et al. 2003). This result would indicate that 
H. influenzae has played a role in over half the episodes of infection in the New 
Zealand children involved in this study.  
The culture-independent results of this study show the majority of bacteria in 
higher proportions than those in a past study of New Zealand children. S. 
pneumoniae colonisation was the only exception, in which only 9% of MEEs 
were positive in this study, compared to 8% of total samples in the previous study 
(Watson et al. 1996). S. pneumoniae had the lowest colonisation percentage of the 
three known pathogens. This decrease could indicate the efficacy of the 
immunisation protocol. However, the immunization results reported here, and in 
     Chapter 4: Discussion 
78 
 
other studies, would suggest immunisation has not played a significant role in this 
decrease (Kuo et al. 2011).  
A study of the Australian Aboriginal population also noted the absence in S. 
pneumoniae colonisation (Stuart et al. 2003). Stuart et al (2003) analysed their 
samples using culture techniques, and thought the decreased numbers of S. 
pneumoniae may have been due to antibiotic use. The use of non-culture based 
techniques in this current study was intended to minimise the influence of 
previously used antibiotics on results. Whether this was successful is unknown. 
 Polymicrobial infections 4.2.3
The polymicrobial nature of OM has been well documented. Results of a previous 
study looking at the polymicrobial nature of MEEs in New Zealand children 
contrast with the results reported here (Cecire et al. 2009). Cecire et al (2009) 
found A. otitidis in the majority of samples, and the NP pathogens alone in very 
few. This current study found 21% of MEE had H. influenzae alone, and 21% had 
Moraxella spp. alone. 
Further, the previous study found S. pneumoniae colonisation either as the sole 
pathogenic agent, or with A. otitidis, to be higher than that of both other NP 
bacteria. This is in direct contrast to the current study, which found no instances 
of S. pneumoniae colonising without one or both of the other NP bacteria and no 
colonisation of the A. otitidis and S. pneumoniae duo in the MEE. It is important 
to note that the primer used for M. catarrhalis in the previous study was the same 
as used for this current research. Therefore, these previous results, specified as M. 
catarrhalis, identified this genus with the same specificity as this research. 
In vitro, it has been observed that H. influenzae and Moraxella spp. can co-exist in 
a mutually beneficial manner (Armbruster et al. 2010). This polymicrobial 
combination was the most observed of the control NP samples, and the second 
equal most observed in the NP of OM patients, after Moraxella spp. alone. Further, 
all sampled sites and groups had at least one patient with this polymicrobial status. 
This suggests these bacteria do co-exist readily. However, associations with OM 
cannot be made based on these results as the control NP was populated at close to 
double the frequency of the NP of OM patients. 
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 Limitations to non-culture based results 4.2.4
Small numbers of participants, lack of antibiotic resistance profiles, no 
information on viral prevalence, or the presence of a biofilm, create limitations to 
the results of this current research. Further, the extraction technique was not tested 
for its efficiency on middle ear effusions, and therefore may have been biased or 
less efficient at lysing bacteria in a mucus or biofilm layer. 
Results may have been influenced by the necessity to freeze the samples before 
analysis. Samples were frozen for storage purposes, and if they had been extracted 
or cultured shortly after collection, results may have varied. The true impact of 
this storage in the samples is unknown. 
The small number of cultured samples made the strength of statistical significance 
calculations in comparing culture and non-culture based techniques for bacterial 
identification pointless, and therefore these calculations were not completed.  
Some studies have looked specifically at a type of OM, for example, Ashhurst-
Smith et al (2007) looked specifically at children with OME in relation to A. 
otitidis prevalence (Ashhurst-Smith et al. 2007). This current study combined a 
number of different forms of OM, and not just the chronic or the acute forms 
separately, when comparing to OM-free controls. This could have had some 
influence on the results. 
4.3 Previous findings on S. pneumoniae prevalence and 
vaccination status 
A modest 6-7% decrease in OM episodes has been seen in children vaccinated 
with PCV7 (Binks et al. 2011). A recent study by Laufer et al (2011) used 
Roche/454 Life Science pyrosequencing to take an in-depth look into the bacterial 
colonisation of the NP in children with an URTI (Laufer et al. 2011). 43.5% of the 
children in their study population were culture positive for S. pneumoniae, despite 
88% of these children having complete PCV7 vaccination status. Data from the 
proportion of the immunised children that were positive for S. pneumoniae was 
not presented.  
A study of 292 patients in the USA found no statistically significant differences 
between the S. pneumoniae colonisation and vaccination status in children, though 
a slight decrease in colonisation rate was present in vaccinated children (Poetker 
     Chapter 4: Discussion 
80 
 
et al. 2005). In this study, which utilized culture techniques, 4% of vaccinated 
children were positive for S. pneumoniae colonisation of the MEE, while positives 
were found in 7.1% of non-vaccinated children (all children were OM sufferers). 
The same trend was found in colonisation of the OE (2.5% vs. 6.5%, respectively).  
 Comparisons with PCV7 vaccination and S. pneumoniae 4.3.1
prevalence in this study 
14 control participants and 13 OM patients were fully vaccinated. This represents 
a modest decrease in the number of children vaccinated who have OM, as 38% of 
controls were vaccinated, compared to 30% of OM patients. This is slightly higher 
than the 6-7% decrease of OM episodes previously reported in vaccinated 
children (Binks et al. 2011). 
The limited influence the PCV7 vaccination seems to have had on S. pneumoniae 
colonisation, and in preventing OM, is in agreement with the results of past 
studies (Binks et al. 2011; Laufer et al. 2011). Episodes of OM due to non-
vaccinated serotypes, and other pathogenic species, have increased since the 
introduction of the PCV7 vaccine (Vergison 2008). Serotypical information from 
the positive results in this current research was not collected. 
This current research found S. pneumoniae present in 16% of vaccinated NPs of 
patients with OM, and 21% of non-vaccinated OM patients. This slight decrease 
in vaccinated participants agrees with previous results from the OE and MEE 
(Poetker et al. 2005). However, when looking at the MEE of the OM patient 
group, 25% of vaccinated patients tested positive, compared to 6% of non-
vaccinated patients. The results from the control study group also suggest a 
positive relationship between vaccination and S. pneumoniae colonisation, with 
46% of vaccinated control NPs being positive, compared to 5% of non-vaccinated. 
The patient numbers involved in this current study are not substantial enough to 
determine the true effects of the PCV7 vaccine throughout the New Zealand 
population. Therefore, statistical significance between patients of different 
vaccination status was not determined. Further research would be necessary to 
determine the true effect vaccination has had on the pneumococcal status of New 
Zealand children. 
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4.4 Sau-PCR 
Sau-PCR has never been completed on samples of the OE, NP or MEE before. 
Comparisons to previous results are therefore unable to be made. Furthermore, the 
paper by Corich et al (2005) used this technique on cultured isolates of bacteria, 
none of which having consequence to this study (Corich et al. 2005). 
Corich et al (2005) suggests use of the Sau-PCR protocol on virtually any 
culturable organism (Corich et al. 2005). This current study demonstrates the 
efficacy of use on mixed environmental samples not from culture. The potential 
for organism identification through comparisons of unique banding patterns is 
also not to be overlooked.  
4.5 Conclusions 
Moraxella spp. colonised the OE of control participants more regularly than the 
OE of OM patients (58% vs. 33%). This difference was found to be statistically 
significant (p= 0.0023). H. influenzae also demonstrated a number of positives in 
the OE of control participants. How these bacteria got into the OE in a large 
number of participants without an episode of OM is unknown.  
Differences between the colonisation of the outer ear canal and nasopharyngeal 
body sites were found at a statistically significant level in control participants with 
A. otitidis (p=0.0433), C. auris (p=0.0000), T. otitidis (p=0.0050) and Moraxella 
spp. (p=0.0005). Of the same body sites in otitis media patients, only the 
colonisation of C. auris (p=0.0002) and T. otitidis (p=0.0004) were found to be 
statistically significant. As the OM group displays less statistically significant 
differences in colonisation between anatomical sites, it could be assume there is 
an increased likelihood for bacteria to get into the OE from the NP or vice versa 
during episodes of OM. 
The colonisation of the NP by the three OE commensals is low in both study 
groups. Statistically significant differences between the OE and NP can be seen in 
both study groups for all three bacteria, except A. otitidis in the OM group. This 
may demonstrate the increased propensity for its establishment in the NP after an 
episode of OM, as this site has become accessible to it.  
H. influenzae and Moraxella species were detected the most of all species in the 
MEE. S. pneumoniae had the lowest prevalence of all the nasopharyngeal 
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pathogens in all sites tested. Vaccination status does not appear to be an 
explanation for this. 
Culture results yielded little information of the six species of interest. Commensal 
bacteria of the upper respiratory tract, some with the potential for limiting OM 
occurrence were cultured. These results indicate that New Zealand children have 
similar colonisation to those of worldwide studies. 
Sau-PCR results indicated the similarities and differences between the body sites 
in terms of species diversity (represented by an increased or decreased number of 
bands in the gel profile). Isolated species profiles which had a more unique 
banding pattern allowed for an estimation of their presence in DNA samples from 
direct extraction. Cloning experiments failed to yield information on the most 
dominant PCR products. 
4.6 Future Research 
Further research using a larger study group to look into the differences in 
colonisation between OM-patients and OM-free controls is necessary.  
Information that includes the carriage rates of the potential „interfering‟ organisms 
Dolosigranulum pigrum and Corynebacterium pseudodiphtheriticum could be 
useful in determining the role of these bacteria, whose colonisation has been 
associated with a decrease in OM frequency. 
Information on the antibiotics participants have been prescribed prior to sample 
collection, as well as antibiotic susceptibility profiles on cultured bacteria, would 
increase understanding on how to treat these infection in New Zealand children. 
Determination of an immune response against the two OE commensals C. auris 
and T. otitidis may provide further insight into the pathogenic status of these 
organisms, as would complete genome sequencing to determine the presence of 
pathogenic genes. Determination of the genes that are „switched on‟ using cDNA 
analysis could provide additional insight into pathogenic abilities. 
Further research into vaccine efficiency using larger patient numbers is required. 
Information on the dynamics of the biofilm formed during OM in the NP and the 
MEE could increase the understanding of infection, and provide further insight for 
more effective treatments. 
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6 Appendix I: Ethics information 
The following information sheets and consent forms were given to the parents of 
the children undergoing the operations pertaining to their AOM, OME, or RAOM. 
Parents of control patients who were undergoing non-middle ear infection related 
operations were given the control version of the information and consent forms. 
Version 2 of these documents was approved by the Northern Y Regional Ethics 
committee, as well as the University of Waikato Ethics committee. 
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School of Science & Engineering  
The University of Waikato 
Private Bag 3105 
Hamilton 
New Zealand 
Phone +64 7 838 4148 
 
Information Sheet for Patients 
Version 2 (05/05/2011) 
 
Project Title 
 
Do bacteria of the external ear canal contribute to otitis media in children?  
 
Principal Investigator 
 
Rebecca White (Master of Science student) 
Molecular Genetics Laboratory (C.2.03) 
Department of Biological Sciences 
The University of Waikato 
Day Ph: (07) 838 4466 Evening Phone: 027 3669156 
 
Introduction 
 
You/your child are invited to participate in a study that will investigate the influence that 
outer ear bacteria have on middle ear disease. 
 
Participation and Confidentiality 
 
 Your child’s participation is entirely voluntary. 
 If you agree to allow your child to take part you are free to withdraw your child 
from the study at any time, without having to give a reason and this will in no 
way effect your child’s future health care. 
 There will be neither cost nor payment towards your child’s participation. 
 No material which could personally identify your child will be used in any reports 
on this study.  
 Results will be kept confidential throughout the duration of the study and stored 
in a secure location after completion of the study. 
 If you would like to know the results of the study, the research student or the 
supervisor will give you a copy of the final report once the report is finished or 
published, or discuss the results with you in person. 
 
Project Purpose 
 
Middle ear diseases are among the most common diseases found in infants and 
children. The influence of outer ear bacteria on the recurrence, progression and 
outcome of the disease is currently uncertain and controversial. Normal pathogens of 
middle ear infections come from the nasopharynx, however some external ear canal 
bacteria have been found in middle ear fluids during infection (see diagram 1). This 
research looks to profile the bacteria of the nasopharynx and outer ear canal to 
determine a relationship between the bacteria present in these areas and middle ear 
disease prevalence.  
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Diagram 1 – Indicates the three main areas of study:  
 The nasopharynx, where bacteria involved in middle ear infection normally 
reside. These remain in a non-pathogen state until a viral attack (such as the 
common cold), when they can become pathogenic. 
 The middle ear, where infection occurs. 
 And the outer ear or external ear canal. This is where the potential pathogens 
reside, and the area of most interest in this research. 
 
Nasopharynx 
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Project Method 
 
During the surgical procedures, a health practitioner will take a swab of your child’s 
external ear canal. A nasopharyngeal sample will be retrieved by insertion of a fine swab 
through the nose. If your child is having grommets inserted, a sample of your child’s 
middle ear fluid will also be taken. This will not result in an increased time in theatre, 
nor will it influence recovery time. These samples will then be transported to the 
Molecular Genetics Laboratory at the University of Waikato for -80° storage until 
processing can begin. Bacteria from these samples will then be cultured or identified 
through molecular genetics techniques. These techniques will only be looking at the 
DNA of the bacterial species in your child’s samples, not your child’s DNA. 
Approximately 200 patients will be involved in this study. These will be either patients 
admitted to Waikato Hospital for surgery due to middle ear disease (cases) or patients 
admitted to hospital with no significant history of middle ear disease (controls). 
 
Benefits and Risks 
 
The results of this proposed study could potentially improve the understanding of the 
factors that cause the recurrence of middle ear disease. Antibiotic therapy currently 
used to treat this disease could potentially be improved if a better understanding of the 
bacteria involved is achieved.  
No side effects or risks are anticipated in this study.  
 
Definition of Scientific Terms 
 
Pathogens – disease causing micro organism 
Nasopharynx – the area that joins the nasal cavity with the throat. 
Nasopharyngeal – The mucosal layer of the nasopharynx. 
 
Declaration  
 
In the unlikely event of a physical injury as a result of your child’s participation in this 
study, you may be covered by ACC under the Injury Prevention, Rehabilitation and 
Compensation Act 2001. ACC cover is not automatic and your case will need to be 
assessed by ACC according to the provisions of the 2002 Injury Prevention 
compensation. This depends on a number of factors. ACC usually provides only partial 
reimbursement of costs and expenses. Therefore, there may be no lump sum 
compensation payable. There is no cover for mental injury unless it is a result of physical 
injury. If you have ACC cover, generally this will effect your right to sue the investigators. 
If you have any questions about ACC, contact your nearest ACC office or the 
investigator.  
 
Statement of Ethical Approval 
This project is has received ethical approval from the Northern Y Regional Ethics 
Committee. If you have any questions or concerns regarding your rights as a participant 
in this study you may wish to contact a Health and Disability Advocate of Mid and Lower 
North Island on 0800 42 36 38. 
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Consent form 
Version 2 13/06/2011 
 
Project: Do commensal bacteria of the external ear canal contribute to middle ear 
infection in children? 
 
Research Student:  
Rebecca White 
Supervisor:  Dr. Ray T. M. Cursons 
Location: Molecular Genetics Lab (C2.03), the University of Waikato 
Ph: (07) 838 4466 ext 8482 
 
I have read and I understand the information sheet for caregivers volunteering their 
children to take part in the study looking to identify the potential role of external ear 
bacteria in middle ear disease. I have had the opportunity to discuss this study. I am 
satisfied with the answers I have been given.  
          
 Yes/No 
 
I understand that taking part in this study is completely voluntary and that I may 
withdraw my child from the study at any time and this will in no way effect their future 
health care. 
          
 Yes/No 
 
I understand that the participation of my child in the study is confidential and that no 
material which could identify them will be used in any reports on this study. 
          
 Yes/No 
 
I have had time to consider whether to allow my child to take part. I know whom to 
contact if my child has any side effects from the study. 
          
 Yes/No 
I understand the ACC compensation provisions for this study. 
          
 Yes/No 
 
I wish to receive a copy of the results or to discuss the outcomes of the study with the 
researcher. 
 
          
 Yes/No 
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I..........................................................................................................hereby consent to my  
 
child, ........................................................................................................, taking part in 
this study. 
 
Date: .......................................................................................................... 
 
 
Signature: .......................................................................................................... 
 
Project explained by: .......................................................................................................... 
 
Project role: .......................................................................................................... 
 
 
Signature: .......................................................................................................... 
 
Date: .......................................................................................................... 
 
Contact details (please feel free to contact the researchers if you have any questions 
about this study): 
 
Rebecca White 
Location: Molecular Genetics Lab (C2.03), the University of Waikato 
Ph: (07) 838 4466 ext 8482 
Email: rkw14@waikato.ac.nz 
 
Dr. Ray T. M. Cursons 
Location: Molecular Genetics Lab (C2.03), the University of Waikato 
Ph: (07) 838 4466 ext 8482 
Email: r.cursons@waikato.ac.nz 
 
Dr. Tony Cecire 
Location: Anglesea Clinic, Cnr Anglesea and Thackeray Streets, Hamilton.  
Ph: (07) 839 2152 
Email: Cecire@xtra.co.nz 
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Information Sheet for Control Patients of Middle ear 
infection study 
Version 2 (05/05/2011) 
 
Project Title 
Do bacteria of the external ear canal contribute to otitis media in children?  
 
Principal Investigator 
 
Rebecca White (Master of Science student) 
Molecular Genetics Laboratory (C.2.03) 
Department of Biological Sciences 
The University of Waikato 
Day Ph: (07) 838 4466 Evening Phone: 027 3669156 
 
Introduction 
 
You/your child are invited to participate in a study that will investigate the influence that 
outer ear bacteria have on middle ear disease. 
 
Participation and Confidentiality 
 
 Your child’s participation is entirely voluntary. 
 If you agree to allow your child to take part you are free to withdraw your child 
from the study at any time, without having to give a reason and this will in no 
way effect your child’s future health care. 
 There will be neither cost nor payment towards your child’s participation. 
 No material which could personally identify your child will be used in any reports 
on this study.  
 Results will be kept confidential throughout the duration of the study and stored 
in a secure location after completion of the study. 
 If you would like to know the results of the study, the research student or the 
supervisor will give you a copy of the final report once the report is finished or 
published, or discuss the results with you in person. 
 
Project Purpose 
 
Middle ear diseases are among the most common diseases found in infants and 
children. The influence of outer ear bacteria on the recurrence, progression and 
outcome of the disease is currently uncertain and controversial. Normal pathogens of 
middle ear infections come from the nasopharynx, however some external ear canal 
bacteria have been found in middle ear fluids during infection (see diagram 1). This 
research looks to profile the bacteria of the nasopharynx and outer ear canal to 
determine a relationship between the bacteria present in these areas and middle ear 
disease prevalence.  
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Diagram 1 – Indicates the three main areas of study:  
 The nasopharynx, where bacteria involved in middle ear infection normally 
reside. These remain in a non-pathogen state until a viral attack (such as the 
common cold), when they can become pathogenic. 
 The middle ear, where infection occurs. 
 And the outer ear or external ear canal. This is where the potential pathogens 
reside, and the area of most interest in this research. 
 
Nasopharynx 
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Project Method 
During your child’s surgical procedure, a health practitioner will take a swab of your 
child’s external ear canal. A nasopharyngeal sample will also be retrieved by insertion of 
a fine swab through the nose. These painless samples will be taken when your child is 
under anaesthetic, in order to decrease any discomfort they may feel. This will not result 
in an increased time in theatre, nor will it influence recovery time. These samples will 
then be transported to the Molecular Genetics Laboratory at the University of Waikato 
for -80° storage until processing can begin. Bacteria from these samples will then be 
cultured or identified through molecular genetics techniques. These techniques will only 
be looking at the DNA of the bacterial species in your child’s samples, not your child’s 
DNA. Approximately 200 patients will be involved in this study. These will be either 
patients admitted to Waikato Hospital for surgery due to middle ear disease (cases) or 
patients admitted to hospital with no significant history of middle ear disease, as in the 
case of your child (controls).  
 
Benefits and Risks 
 
The results of this proposed study could potentially improve the understanding of the 
factors that cause the recurrence of middle ear disease, and although will not benefit 
your child directly, may help in the treatment of this prolific disease. Antibiotic therapy 
currently used to treat this form of infection could potentially be improved if a better 
understanding of the bacteria involved is achieved.  
No side effects or risks are anticipated in this study.  
 
Definition of Scientific Terms 
 
Pathogens – disease causing micro organism 
Nasopharynx – the area that joins the nasal cavity with the throat. 
Nasopharyngeal – The mucosal layer of the nasopharynx. 
 
Declaration  
 
In the unlikely event of a physical injury as a result of your child’s participation in this 
study, you may be covered by ACC under the Injury Prevention, Rehabilitation and 
Compensation Act 2001. ACC cover is not automatic and your case will need to be 
assessed by ACC according to the provisions of the 2002 Injury Prevention 
compensation. This depends on a number of factors. ACC usually provides only partial 
reimbursement of costs and expenses. Therefore, there may be no lump sum 
compensation payable. There is no cover for mental injury unless it is a result of physical 
injury. If you have ACC cover, generally this will effect your right to sue the investigators. 
If you have any questions about ACC, contact your nearest ACC office or the 
investigator.  
 
Statement of Ethical Approval 
This project has received ethical approval from the Northern Y Regional Ethics 
Committee. If you have any questions or concerns regarding your rights as a participant 
in this study you may wish to contact a Health and Disability Advocate of Mid and Lower 
North Island on 0800 42 36 38. 
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Consent form 
Version 2 13/06/2011 
 
Project: Do commensal bacteria of the external ear canal contribute to middle ear 
infection in children? 
 
Research Student:  
Rebecca White 
Supervisor:  Dr. Ray T. M. Cursons 
Location: Molecular Genetics Lab (C2.03), the University of Waikato 
Ph: (07) 838 4466 ext 8482 
 
I have read and I understand the information sheet for caregivers volunteering their 
children to take part in the study looking to identify the potential role of external ear 
bacteria in middle ear disease. I have had the opportunity to discuss this study. I am 
satisfied with the answers I have been given.  
          
 Yes/No 
 
I understand that taking part in this study is completely voluntary and that I may 
withdraw my child from the study at any time and this will in no way effect their future 
health care. 
          
 Yes/No 
 
I understand that the participation of my child in the study is confidential and that no 
material which could identify them will be used in any reports on this study. 
          
 Yes/No 
 
I have had time to consider whether to allow my child to take part. I know whom to 
contact if my child has any side effects from the study. 
          
 Yes/No 
I understand the ACC compensation provisions for this study. 
          
 Yes/No 
 
I wish to receive a copy of the results or to discuss the outcomes of the study with the 
researcher. 
          
 Yes/No  
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I..........................................................................................................hereby consent to my  
 
child, ........................................................................................................, taking part in 
this study. 
 
Date: .......................................................................................................... 
 
 
Signature: .......................................................................................................... 
 
Project explained by: .......................................................................................................... 
 
Project role: .......................................................................................................... 
 
 
Signature: .......................................................................................................... 
 
Date: .......................................................................................................... 
 
Contact details (please feel free to contact the researchers if you have any questions 
about this study): 
 
Rebecca White 
Location: Molecular Genetics Lab (C2.03), the University of Waikato 
Ph: (07) 838 4466 ext 8482 
Email: rkw14@waikato.ac.nz 
 
Dr. Ray T. M. Cursons 
Location: Molecular Genetics Lab (C2.03), the University of Waikato 
Ph: (07) 838 4466 ext 8482 
Email: r.cursons@waikato.ac.nz 
 
Dr. Tony Cecire 
Location: Anglesea Clinic, Cnr Anglesea and Thackeray Sts, Hamilton.  
Ph: (07) 839 2152 
Email: Cecire@xtra.co.nz 
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7 Appendix II: Patient Information 
Patient information was obtained that was relevant to the study. 42 OM patients 
were included in this study, as well as 36 control patients. Control patient #1C did 
not have their colonisation data included in analysis, due to OM history. Some 
patients had both culture and direct DNA analysis, while others had one or the 
other.  
Note two control patients that had a history of OM were not excluded as this 
episode had occurred in the years previous to sampling. Further, controls with an 
unspecified history of OM did not present with any symptoms of infection at the 
time of sampling, and were deemed appropriate for use as controls by the health 
practitioner. 
The following abbreviations were used in this section: 
R me – Right middle ear effusion 
L me – Left middle ear effusion 
RE – Right outer ear canal 
LE – Left outer ear canal 
NP – Nasopharyngeal sample 
Transoral – sample taken via the oral cavity 
Transnasal – Sample taken via the nasal cavity 
TAH – Tonsils and adenoid hypertrophy. 
Flat tymps – Flat tympanometry. 
Ads – Adenoidectomy.  
Tonsils – Tonsillectomy. 
Grommets – Ventilation tube insertion. 
UTD – Immunisations up to date. 
OD – Immunisations over due by the months specified. 
VT – Ventilation tube insertion (Grommets). 
NS – Not specified. 
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Patient Sex Age (months) Diagnosis/Procedure MEE sampled? Effusion status History Ethnicity PCV7 dose Imms
1 F 38 OME R me mucoid nil previous Maori 0 UTD
L me dry
2 M 59 OME R me mucoid Grommets,Tonsils Maori 0 UTD
L me mucoid Ads 2007
3 M 52 NS No - NS NZ Euro 0 UTD
4 M 91 NS R me NS NS NZ Euro 0 UTD
5 M 58 OME R me bloody nil NZ Euro 0 UTD
Grommets/Tonsils/Ads L me dry
6 F 11 RAOM R me mucoid nil previous Maori 0 Unimmunised
L me mucoid
7 M 14 RAOM R me dry nil previous NZ Euro 4 UTD
L me dry
8 M 44 OME No mucopurulent previous VT x2 NZ Euro 0 UTD
9 M 11 RAOM R me serous nil previous NZ Euro 4 UTD
L me serous
10 M 45 OME,TAH R me mucopurulent previous VTx1 NZ Euro 0 UTD
L me mucopurulent
11 F 17 RAOM R me dry nil previous NZ Euro 4 UTD
L me dry
12 M 14 RAOM R me mucoid nil previous Maori 4 UTD
L me mucoid
13 M 42 OME R me mucoid previous VTx1 NZ Euro 0 UTD
L me mucoid
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Patient Sex Age (months) Diagnosis/Procedure MEE sampled? Effusion status History Ethnicity PCV7 dose Imms
14 M 51 OME R me mucoid NS NZ Euro 0 UTD
L me mucoid
15 M 46 Grommets R me mucoid nil previous NZ Euro 0 UTD
Adenoids L me dry
16 M 37 Bilateral Grommets R me dry nil previous Maori 4 UTD
L me dry flat tymps
17 M 43 Bilateral Grommets R me dry nil previous Maori 0 UTD
rAOM L me dry
18 F 73 OME R me mucoid nil previous NZ Euro 0 UTD
L me mucoid
19 F 18 RAOM R me mucoid NS NZ Euro 0 UTD
L me dry
20 F 68 OME R me mucoid Grommets x1 pair NZ Euro 0 UTD
L me dry
21 M 32 OME R me mucoid NS NZ Euro 0 UTD
L me mucoid
22 F 37 OME R me mucoid NS Maori 0 UTD
L me mucoid
23 F 34 OME R me dry grommets x1 NZ Euro 4 UTD
L me dry
24 F 44 OME R me mucoid NS NZ Euro 0 UTD
L me mocoid
25 F 14 rAOM R me dry nil previous NZ Euro 4 UTD
Bilateral Grommets L me dry rAOM
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Patient Sex Age (months) Diagnosis/Procedure MEE sampled? Effusion status History Ethnicity PCV7 dose Imms
26 M 17 OME R me mucoid RAOM + OME NZ Euro 4 UTD
Bilateral Grommets L me mucoid flat tymps
27 M 39 OME R me mucopus RAOM + OME NZ Euro 0 UTD
Grommets/Tonsils/Ads L me mucopus flat tymps
28 M 50 OME R me dry OME NZ Euro 0 UTD
Grommets/Adenoids L me dry flat tymps
29 F 11 Bilateral Grommets R me perforation+discharge nil previous Maori 4 UTD
rAOM L me dry
30 M 18 Bilateral Grommets R me dry nil previous Maori 4 UTD
rAOM L me dry
31 M 21 Bilateral Grommets R me dry nil previous NZ Euro 4 UTD
rAOM L me dry
32 F 42 OME R me dry nil NZ Euro 0 UTD
Grommets/Ads/Tonsils L me mucoid
33 M 17 Bilateral Grommets R me mucoid nil previous NZ Euro 1 INCOMPLETE
rAOM L me mucoid
34 M 34 OME R me mucoid nil previous Maori 3 UTD
Grommets/Ads L me mucoid
35 F 33 OME R me scant nil previous NZ Euro 4 UTD
L me mucopurulent
36 F 45 Gs endo Ads R me seropu nil previous NZ Euro 0 UTD
rAOM L me mucoid
37 M 59 OME, ATH R me mucoid nil NZ Euro 0 UTD
L me mucoid
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Patient Sex Age (months) Diagnosis/Procedure MEE sampled? Effusion status History Ethnicity PCV7 dose Imms
38 M 56 OME R me mucoid previous rAOM NZ Euro 0 UTD
L me mucoid in infancy
39 F 45 AOM R me insufficient DNA NZ Euro 4 UTD
Grommets/Ads/Tonsils L me insufficient DNA
40 M 110 OME,tonsillitis R me scant NS NZ Euro 0 UTD
L me mucoid
41 M 60 OME R me insufficient DNA NS Maori 0 UTD
Grommets L me insufficient DNA
42 M 94 OME R me dry previous VTx2 Maori 0 UTD
L me mucoid
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Sample Sex Age (months) Sites sampled History Ethnicity PCV7 doses Immunization
1C M 45 RE 4-5 AOM in 3 years NZ Euro 0 UTD
LE Excluded from study 
NP due to OM history
2C M 40 RE nil previous NZ Euro 4 UTD
LE
NP
3C M 55 RE nil NZ Euro 0 UTD
LE
NP
4C M 25 RE previous AOMx1 Indian 4 UTD
LE
NP
5C M 2 RE nil Euro 0 UNIMMUNISED
LE
NP
6C M 61 RE NS NZ Euro 0 UTD
LE
NP
7C M 68 RE NS Maori 0 UTD
LE
NP
8C M 28 RE NS Cook Island Maori 4 UTD
LE
NP
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Sample Sex Age (months) Sites sampled History Ethnicity PCV7 doses Immunization
9C M 29 RE NS NZ Euro 4 UTD
LE
NP
10C F 18 RE nil Somali 4 UTD
LE nil AOM
NP
11C M 13 RE nil Maori 3 OD 15mnths
LE nil AOM
NP
12C M 33 RE nil Maori 4 UTD
LE
NP
13C M 42 RE nil previous Euro 4 UTD
LE
NP
14C M 48 RE NS Maori 0 UTD
LE
NP
15C M 23 RE nil Polynesian 0 UNIMMUNISED
LE
NP
16C M 46 RE NS NZ Euro 0 UTD
LE
transoral NP
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Sample Sex Age (months) Sites sampled History Ethnicity PCV7 doses Immunization
17C F 53 RE NS NZ Euro 0 UTD
LE
transoral NP
18C M 34 RE NS NZ Euro 4 UTD
LE
transoral NP
19C F 56 RE NS Maori 0 UTD
LE
transoral NP
20C M 51 RE NS Other European 3 UTD
LE
transoral NP
21C M 25 RE NS Maori 4 UTD
LE
transoral nasoph
22C M 39 RE NS NZ Euro 4 UTD
LE
transoral NP
23C M 49 RE NS NZ Euro 0 UNIMMUNISED
LE
transoral NP
24C M 35 RE NS Maori 4 UTD
LE
NP
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Sample Sex Age (months) Sites sampled History Ethnicity PCV7 doses Immunization
25C M 43 RE nil previous Maori-Poly 0 UTD
LE
NP
26C M 48 RE nil previous Euro 0 UTD
LE
NP
27C M 15 RE nil previous Maori 0 UTD
LE
NP
28C M 18 RE nil previous Euro 4 UTD
LE
NP
29C F 73 RE no previous NZ Euro 0 UTD
LE
NP
30C M 47 RE previous VTx1 NZ Euro 0 UTD
LE
NP
31C F 98 RE NS NZ Euro 0 UTD
LE
transoral NP
32C F 80 RE nil previous NZ Euro 0 UTD
LE
transnasal NP
T
a
b
le
 A
II.8
 P
a
tie
n
t in
fo
r
m
a
tio
n
 fo
r
 th
e
 c
o
n
tr
o
l stu
d
y
 g
r
o
u
p
 c
o
n
tin
u
e
d
. 
  
 
1
0
8
 
 
 
Sample Sex Age (months) Sites sampled History Ethnicity PCV7 doses Immunization
33C M 84 RE nil previous Maori 0 UTD
LE
transnasal NP
34C F 32 RE nil previous NZ Euro 4 UTD
transnasal NP
35C F 44 RE NS NZ Euro 4 UTD
LE
NP
36C F 52 RE NS Maori 0 UTD
LE
NP
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8 Appendix III: M. catarrhalis and 
M. nonliquefaciens alignment. 
The primer used in the study by Hendolin et al (1997) targets an area of the 16S 
ribosomal gene in the Moraxella species that is complimentary to both M. 
catarrhalis and M. nonliquefaciens. The 16S alignment of these two species is 
listed below, demonstrating the significant similarities between them both. 
Genbank accession numbers of sequences used: M. catarrhalis, U10876.1. M. 
nonliquefaciens: JN175343.1 
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Figure AIII.1 Alignment between the 16S sequence of M. catarrhalis and M. 
nonliquefaciens. Position of the MS forward primer is highlighted. 
MC      AAAAAATG-TCATGGCTCAGATTGAACGCTGGCGGCAGGCTTAACACATGCAAGTCGAAC 59 
MN      AGAGTTTGATCATGGCTCAGATTGAACGCTGGCGGCAGGCTTAACACATGCAAGTCGAAC 60 
        * *   ** *************************************************** 
 
MC      GAAGTTAGGAAGCTTGCTTCTGATAC-TTAGTGGCGGACGGGTGAGTAATGCTTAGGAAT 118 
MN      GATGAAGTCTAGCTTGCT--AGACGGATTAGTGGCGAACGGGTGAGTAATGCTTAGGAAT 118 
        ** *      ********   **    ********* *********************** 
 
MC      CTGCCTAGTAGTGGGGGATAACTTGGGGAAACCCAAGCTAATACCGCATACGACCTACGG 178 
MN      CTGCCTATTAGTGGGGGATAACGTAGGGAAACTTACGCTAATACCGCATACGACCTACGG 178 
        ******* ************** * *******  * ************************ 
 
MC      GTGAAAGGGGGCTTTTAGCTCTCGCTATTAGATGAGCCTAAGTCGGATTAGCTGGTTGGT 238 
MN      GTGAAAGGGGGCTTTTAGCTCTCGCTAATAGATGAGCCTAAGTCGGATTAGCTAGTTGGT 238 
        *************************** ************************* ****** 
 
MC      GGGGTAAAGGCCTACCAAGGCGACGATCTGTAGCTGGTCTGAGAGGATGATCAGCCACAC 298 
MN      GGGGTAAAGGCCTACCAAGGCGACGATCTGTAGCTGGTCTGAGAGGATGATCAGCCACAC 298 
        ************************************************************ 
 
MC      TGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAGTGGG-AATATTGGACAATG 357 
MN      TGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGGACAATG 358 
        ********************************************* ************** 
 
MC      GGCGAAAGCCTGATCCAGCCATGCCGCGTGTGTGAAGAAGGCCTTTTGGTTGTAAAGCAC 417 
MN      GGCGAAAGCCTGATCCAGCCATGCCGCGTGTGTGAAGAAGGCCTTTTGGTTGTAAAGCAC 418 
        ************************************************************ 
 
MC      TTTAAGTGGGGAGGAAAAGCTTATGGTTAATACCCATAAGCCCTGACGTTACCCACAGAA 477 
MN      TTTAAGTGGGGAGGAAAAGCTTATGGTTAATACCCATAAGCCCTGACGTTACCCACAGAA 478 
        ************************************************************ 
 
MC      TAAGCACCGGCTAACTCTGTGCCAGCAGCCGCGGTAATACAGAGGGTGCAAGCGTTAATC 537 
MN      TAAGCACCGGCTAACTCTGTGCCAGCAGCCGCGGTAATACAGAGGGTGCAAGCGTTAATC 538 
        ************************************************************ 
 
MC      GGAATTACTGGGCGTAAAGCGCGCGTAGGTGGTTATTTAAGTCAGATGTGAAAGCCCCGG 597 
MN      GGAATTACTGGGCGTAAAGCGCGCGTAGGTGGTTATTTAAGTCAGATGTGAAAGCCCCGG 598 
        ************************************************************ 
 
MC      GCTTAACCTGGGAACTGCATCTGATACTGGATAACTAGAGTAGGTGAGAGGGGAGTAGAA 657 
MN      GCTTAACCTGGGAACTGCATCTGATACTGGATAACTAGAGTAGGTGAGAGGGGAGTAGAA 658 
        ************************************************************ 
 
MC      TTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGATGGCGAAGGCAGCT 717 
MN      TTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGATGGCGAAGGCAGCT 718 
        ************************************************************ 
 
MC      CCCTGGCATCATACTGACACTGAGGTGCGAAAGCGTGGGTAGCAAACAGGATTAGATACC 777 
MN      CCCTGGCATCATACTGACACTGAGGTGCGAAAGCGTGGGTAGCAAACAGGATTAGATACC 778 
        ************************************************************ 
 
MC      CTGGTAGTCCACGCCGTAAACGATGTCTACCAGTCGTTGGGTCTTTTAAAGACTTAGTGA 837 
MN      CTGGTAGTCCACGCCGTAAACGATGTCTACCAGTCGTTGGGTCTTTTAAAGACTTAGTGA 838 
        ************************************************************ 
 
MC      CGCAGTTAACGCAATAAGTAGACCGCCTGGGGAGTACGGCCGCAAGGTTAAAACTCAAAT 897 
MN      CGCAGTTAACGCAATAAGTAGACCGCCTGGGGAGTACGGCCGCAAGGTTAAAACTCAAAT 898 
        ************************************************************ 
MC      GAATTGACGGGGGCCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGATGCAACGCGAAG 957 
MN      GAATTGACGGGGGCCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGATGCAACGCGAAG 958 
        ************************************************************ 
 
MC      AACCTTACCTGGTCTTGACATAGTGAGAATCTTGCAGAGATGCGAGAGTGCCTTCGGGAA 1017 
MN      AACCTTACCTGGTCTTGACATAGTGAGAATCTTGCAGAGATGCGAGAGTGCCTTCGGGAA 1018 
        ************************************************************ 
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Figure AIII.2 Alignment between the 16S sequences of M. catarrhalis and M. 
nonliquefaciens continued. 
 
MC      TTCACATACAGGTGCTGCATGGCTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTC 1077 
MN      TTCACATACAGGTGCTGCATGGCTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTC 1078 
        ************************************************************ 
 
MC      CCGCAACGAGCGCAACCCTTTTCCTTAGTTACCAGCGACTCGGTCGGGAACTCTAAGGAT 1137 
MN      CCGCAACGAGCGCAACCCTTTTCCTTAGTTACCAGCGACTCGGTCGGGAACTCTAAGGAT 1138 
        ************************************************************ 
 
MC      ACTGCCAGTGACAAACTGGAGGAAGGCGGGGACGACGTCAAGTCATCATGGCCCTTACGA 1197 
MN      ACTGCCAGTGACAAACTGGAGGAAGGCGGGGACGACGTCAAGTCATCATGGCCCTTACGA 1198 
        ************************************************************ 
 
MC      CCAGGGCTACACACGTGCTACAATGGTTGGTACAAAGGGTTGCTACACAGCGATGTGATG 1257 
MN      CCAGGGCTACACACGTGCTACAATGGTTGGTACAAAGGGTTGCTACACAGCGATGTGATG 1258 
        ************************************************************ 
 
MC      CTAATCTCAAAAAGCCAATCGTAGTCCGGATTGGAGTCTGCAACTCGACTCCATGAAGTC 1317 
MN      CTAATCTCAAAAAGCCAATCGTAGTCCGGATTGGAGTCTGCAACTCGACTCCATGAAGTC 1318 
        ************************************************************ 
 
MC      GGAATCGCTAGTAATCGCAGATCAGAATGCTGCGGTGAATACGTTCCCGGGCCTTGTACA 1377 
MN      GGAATCGCTAGTAATCGCAGATCAGAATGCTGCGGTGAATACGTTCCCGGGCCTTGTACA 1378 
        ************************************************************ 
 
MC      CACCGCCCGTCACACCATGGGAGTTGATCTCACCAGAAGTGGTTAGCCTAACGCAAGAGG 1437 
MN      CACCGCCCGTCACACCATGGGAGTTGATCTCACCAGAAGTGGTTAGCCTAACGCAAGAGG 1438 
        ************************************************************ 
 
MC      GCGATCACCACGGTGGGGTCGATGACTGGGGTGAAGTCGTAACAAGGTAGCCGTAGGGGA 1497 
MN      GCGATCACCACGGTGGGGTCGATGACTGGGGTGAAGTCGTAACAAGGTAGCCGTAGGGGA 1498 
        ************************************************************ 
 
MC      ACCTGCGGTTGGAT--------- 1511 
MN      ACCTGCGGTTGGATCACCTCCTT 1521 
        **************          
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9 Appendix IV: Bacterial prevalence 
results  
Bacterial prevalence results attained from direct swab extraction and nested PCR 
protocol.  
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Table AIV.1 Bacterial prevalence in control patients. R: Removed from study, 
U: Unusable due to contamination or loss of sample, C: culture analysed. 
 
 
Site LE LE LE LE LE LE NP NP NP NP NP NP RE RE RE RE RE RE
Bacteria AO CA HI MS SP TO AO CA HI MS SP TO AO CA HI MS SP TO
Control 1C R R R R R R R R R R R R R R R R R R
Control 2C 1 0 0 1 0 0 0 0 0 1 0 0 1 0 0 0 0 0
Control 3C 1 0 0 1 0 1 U U U U U U 1 0 0 1 0 0
Control 4C 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0
Control 5C 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Control 6C 1 0 0 0 0 1 0 0 0 1 0 0 1 0 0 1 0 0
Control 7C 1 0 0 0 0 0 0 0 1 1 0 0 1 0 0 0 0 0
Control 8C 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0 1 0 0
Control 9C 1 0 0 1 0 0 0 0 0 1 0 0 1 0 0 1 0 0
Control 10C 1 0 0 0 1 0 0 0 0 0 0 0 U U U U U U
Control 11C 0 0 0 0 0 1 0 0 1 1 0 0 0 0 0 0 0 0
Control 12C 1 0 0 1 0 0 0 0 1 1 1 0 1 0 0 1 0 0
Control 13C 0 0 0 1 0 0 0 0 0 1 1 0 0 0 0 1 0 1
Control 14C 0 0 0 1 0 1 0 0 1 1 0 0 0 0 0 1 0 0
Control 15C 1 0 0 1 0 1 0 0 1 1 0 0 1 0 0 1 0 1
Control 16C 1 0 0 0 0 0 0 0 0 1 0 0 1 0 1 1 0 1
Control 17C 1 1 1 1 0 1 0 0 0 1 0 0 1 0 0 1 0 1
Control 18C 1 0 0 1 0 1 0 0 1 1 1 0 1 0 1 1 0 1
Control 19C 1 0 1 1 0 0 0 0 1 1 0 0 1 0 0 0 0 0
Control 20C 1 0 0 1 0 0 0 0 1 0 0 0 1 0 1 1 0 0
Control 21C 0 0 1 1 0 0 0 0 1 1 0 0 0 0 1 1 0 0
Control 22C 0 0 1 1 0 0 0 0 1 1 0 0 0 0 1 1 0 0
Control 23C 1 0 1 1 0 1 0 1 1 1 0 1 1 0 1 1 0 1
Control 24C 1 1 0 0 0 1 1 0 0 1 0 0 1 1 0 0 0 1
Control 25C C C C C C C C C C C C C C C C C C C
Control 26C C C C C C C C C C C C C C C C C C C
Control 27C 0 0 0 1 0 1 0 0 0 1 1 0 0 0 0 1 0 0
Control 28C 0 0 1 1 0 0 0 0 1 1 1 0 1 0 1 1 0 0
Control 29C 1 1 1 1 0 1 0 0 1 1 0 0 1 0 0 0 0 0
Control 30C 1 1 1 0 0 0 0 1 1 1 0 0 1 0 0 0 0 0
Control 31C 1 0 0 0 0 0 1 0 0 1 0 0 1 1 0 0 0 1
Control 32C 1 0 0 0 0 0 0 0 0 1 0 0 1 1 0 0 0 0
Control 33C 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1
Control 34C 0 0 0 0 0 0 0 0 1 1 1 0 U U U U U U
Control 35C 0 0 1 0 0 1 0 0 0 1 1 0 0 1 1 0 0 1
Control 36C 1 1 1 1 0 1 0 0 1 1 0 0 1 0 1 1 0 1
Total of positives 20 5 10 19 1 13 2 2 16 28 7 1 21 4 9 18 0 11
  
1
1
4
 
 
Site LE LE LE LE LE LE LM LM LM LM LM LM NP NP NP NP NP NP RE RE RE RE RE RE RM RM RM RM RM RM
Bacteria AO CA HI MS SP TO AO CA HI MS SP TO AO CA HI MS SP TO AO CA HI MS SP TO AO CA HI MS SP TO
OM Patient 1 0 0 1 1 1 0 0 0 0 0 0 0 C C C C C C C C C C C C
OM Patient 2 C C C C C C C C C C C C 1 0 0 0 0 1 0 0 0 1 0 0
OM Patient 3 C C C C C C C C C C C C C C C C C C
OM Patient 4 1 0 0 1 0 0 C C C C C C 0 0 0 0 0 0 0 0 0 1 0 0
OM Patient 5 1 0 0 0 0 1 1 0 1 0 0 1 1 0 1 0 0 1 0 0 0 0 0 1
OM Patient 6 C C C C C C 0 0 1 0 0 0 C C C C C C C C C C C C 0 0 1 0 1 1
OM Patient 7 1 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 0 0
OM Patient 8 C C C C C C 0 0 0 0 0 0
OM Patient 9 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0
OM Patient 10 0 0 0 0 0 0 1 0 1 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0
OM Patient 11 1 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0
OM Patient 12 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
OM Patient 13 0 0 0 1 0 0 0 0 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0
OM Patient 14 0 0 1 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0
OM Patient 15 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
OM Patient 16 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0
OM Patient 17 1 0 0 1 0 1 0 0 1 1 0 0 1 0 0 1 0 1
OM Patient 18 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0
OM Patient 19 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
OM Patient 20 1 0 0 0 0 0 0 0 0 0 0 0
OM Patient 21 1 0 0 0 0 0 0 0 1 0 0 0 0 0 1 1 0 0 1 0 0 0 0 0 1 0 1 0 0 0
OM Patient 22 C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C
OM Patient 23 C C C C C C C C C C C C C C C C C C
OM Patient 24 0 0 0 0 0 0 0 0 1 0 0 0 1 0 1 1 0 0 0 0 1 0 0 0 0 0 1 0 0 0
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5
 
Site LE LE LE LE LE LE LM LM LM LM LM LM NP NP NP NP NP NP RE RE RE RE RE RE RM RM RM RM RM RM
Bacteria AO CA HI MS SP TO AO CA HI MS SP TO AO CA HI MS SP TO AO CA HI MS SP TO AO CA HI MS SP TO
OM Patient 25 0 0 1 0 0 0
OM Patient 26 1 0 0 1 0 1 0 0 1 1 0 1 0 0 0 1 0 0 1 0 0 0 0 1 0 0 0 1 0 1
OM Patient 27 1 0 1 1 0 1 0 0 0 0 0 0 0 0 0 1 1 0 1 0 0 1 0 0 0 0 0 1 1 0
OM Patient 28 1 0 0 0 0 1 0 0 0 1 1 0 1 0 0 1 0 1
OM Patient 29 0 0 0 1 0 0 0 0 1 1 0 0 1 1 1 1 0 1
OM Patient 30 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0
OM Patient 31 1 0 0 1 0 1 0 0 1 1 0 0 0 0 0 1 0 0 1 0 0 1 0 0 0 0 0 1 0 0
OM Patient 32 1 1 1 1 0 1 1 0 1 0 0 0 0 0 1 1 0 0 1 1 0 0 0 1
OM Patient 33 0 0 0 0 0 1 0 0 0 1 0 1 0 0 0 1 1 1 0 0 0 0 0 1 0 0 1 1 0 1
OM Patient 34 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 1 1 0 0 0 0 1 1 1 1 0 1
OM Patient 35 1 1 0 0 0 0 1 1 1 1 1 1 0 1 0 1 0 0 1 0 1 1 0 0
OM Patient 36 1 0 1 1 0 0 0 0 1 0 0 0 0 0 1 0 0 0 1 0 1 1 0 0 0 0 1 1 1 0
OM Patient 37 1 0 1 1 0 0 1 0 1 1 0 0 0 0 1 1 1 0 0 1 0 0 0 0
OM Patient 38 1 0 1 0 0 1 0 0 0 1 0 0 0 0 1 1 1 0 1 0 0 0 0 1 0 0 0 1 0 0
OM Patient 39 0 0 1 1 0 1 0 0 1 1 1 0 0 1 0 1 0 1
OM Patient 40 1 0 0 0 0 1 0 0 0 1 0 0 0 0 1 1 1 0 1 1 0 1 0 1
OM Patient 41 0 0 0 1 0 0 0 1 0 1 0 0 0 0 0 1 0 0 0 1 0 0 0 0
OM Patient 42 1 1 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0 1
Total positives 19 3 7 12 1 12 4 2 13 9 1 3 3 4 16 23 8 2 20 6 5 10 0 11 3 2 9 10 3 6
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10 Appendix V: Sequencing results 
Electropherogram results are provided in a subset of samples. 
Section 1 
Sequencing results for organisms isolated in pure culture either on 10% Columbia 
blood agar or 10% Columbia chocolate agar. Results are presented as the list from 
the BLAST database, detailing the possible organisms the DNA sequence could 
correspond to. 
Section 2 
The PCR products after a multiplex reaction, isolated separately and sequenced 
for identification. 
Section 3 
A subset of samples that tested positive for the species of interest using the nested 
PCR method were sequenced for accuracy assurance. 702R was used as the 
sequencing primer before the sequences were aligned using BLAST. This section 
details the alignment efficiency of the sequenced DNA with that of the BLAST 
database. 
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Section 1: Results from sequencing species isolated from 
cultured samples. 
 
Figure AV.1 BLAST results for sequence isolated from sample 1RE-A. 
 
Figure AV.2 BLAST results for sequence isolated from sample 8RE-A, after 
Alloiococcus taxid was specified in search conditions. 
 
Figure AV.3 BLAST results for 3LE-C, with a sample of the 
electropherogram data. 
 
Figure AV.4 BLAST results for sequence isolated from sample LE6-A. 
 
Figure AV.5 BLAST results for sequence isolated from sample 1NP-A. 
 
Figure AV.6 BLAST results for sequence isolated from sample 1NP-B. 
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Figure AV.7 BLAST results for sequence isolated from sample 2NP-A when 
searching the whole database (top), and when search parameters are set to 
only Moraxella (taxid:475) (bottom). 
 
Figure AV.8 BLAST result for sequence isolated from sample NP3-A 
 
Figure AV.9 BLAST data on the best alignments with the sequence isolated 
from 26NP-A and electropherogram data from the sequencing results. 
 
Figure AV.10 BLAST results from DNA sequence isolated from organism 
9LM-A, including a sample of electropherogram results. 
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Figure AV.11 Electropherogram data and BLAST results on the organisms 
corresponding to the DNA sequence isolated from organism 26RM-A. 
 
Figure AV.12 Sample of the electropherogram data from 29RM-A 
sequencing and BLAST results of the organisms the sequence aligned with. 
 
Figure AV.13 BLAST results for sequence isolated from sample 25CLE-A. 
Electropherogram data shows a low signal to noise ratio, accounting for the 
lack of 100% identification with BLAST sequences. 
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Figure AV.14 Sample of the electropherogram data from 25CRE-A 
sequencing and BLAST results of the organisms the sequence aligned with. 
 
Figure AV.15 BLAST results for sequence isolated from sample 25CRE-B. 
 
Figure AV.16 BLAST results for sequence isolated from sample 26CRE-A. 
 
Figure AV.17 BLAST results for sequence isolated from sample 26CLE-A. 
 
Figure AV.18 BLAST results for sequence isolated from sample 25CNP-A. 
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Figure AV.19 Electropherogram data and BLAST results of organisms 
corresponding to the DNA sequence isolated from 25CNP-B. 
a) Search parameters set to search all:
b) Search parameters set to align only with Moraxella (taxid:475):
 
Figure AV.20 Electropherogram data and BLAST alignment results of 
organisms corresponding to the DNA sequence isolated from 25CNP-C. a) 
BLAST alignment results with no taxid specified. B) BLAST alignment 
results when specifying Moraxella (taxid:475) in search parameters. 
 
Figure AV.21 BLAST results from the sequence isolated from organism 
26CNP-A, including a sample of the electropherogram results. 
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Figure AV.22 BLAST results for the DNA sequence isolated from organism 
26CNP-B, along with electropherogram data indicating accuracy of sequence. 
Only uncultured species matched this sequence, despite a clear 
electropherogram. 
Section 2: Sequencing results from multiplex PCR 
products 
 
Figure AV.23 BLAST alignment of 237bp PCR product from multiplex PCR. 
Results indicate 99% identity with M. catarrhalis. 
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Figure AV.24 BLAST alignment of 525bp PCR product from multiplex PCR. 
Results indicate a 100% match with H. influenzae. 
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Section 3: Sequencing results from PCR products after 
second amplification round of nested PCR 
 
Figure AV.25 Alignment to BLAST database of sequencing results from PCR 
products of the second step of the nested PCR using SP specific forward 
primer. This DNA was obtained from sample 27RM. 
 
Figure AV.26 Alignment to BLAST database of sequencing results from PCR 
products of the second step of the nested PCR using A. otitidis specific 
forward primer. This DNA was obtained from sample 7CLE. 
Electropherogram demonstrated a low signal to noise ratio, accounting for 
gaps in the sequencing. 
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Figure AV.27 Alignment to BLAST database of sequencing results from PCR 
products of the second step of the nested PCR using MS specific forward 
primer. This DNA was obtained from sample 7CNP. Note the identical 
nature of the alignment to that of Moraxella catarrhalis (see Figure AV.28). 
 
Figure AV.28 Alignment to BLAST database of sequencing results from PCR 
products of the second step of the nested PCR using MS specific forward 
primer. This DNA was obtained from sample 7CNP.Note the identical nature 
of the alignment to that of Moraxella nonliquefaciens (see Figure AV.27). 
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Figure AV.29 Sample 18CLE - alignment to BLAST database of sequencing 
results from PCR products of the second step of the nested PCR using TO 
specific forward primer. Electropherogram data gives an indication of 
sequence clarity.  
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Figure AV.30 Sample 17CLE - alignment to BLAST database of sequencing 
results from PCR products of the second step of the nested PCR using HI 
specific forward primer. Electropherogram results indicate sequence clarity. 
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Figure AV.31 Sample 23CNP - Alignment to BLAST database of sequence 
from PCR products of the second step of the nested PCR using CA specific 
forward primer. Electropherogram results indicating clarity of the sequence. 
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11 Appendix VI: Statistics 
The following are the statistical reports from the software program Statistica. The 
chi-squared test p values were used when comparing the outer ear and 
nasopharyngeal cavities between the study groups, while the McNemar‟s test p 
values were used when comparing the studied sites within the study groups. 
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Table VI.1 Statistica report tables showing input values and p values when 
comparing colonisation of the nasopharynx and the outer ear canal in the 
OM patient study group. The McNemar’s Chi-square was the p value used 
here. 
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Table VI.2 Statistica report tables showing input values and p values for 
comparisons between the colonisation of the nasopharynx and the outer ear 
canal in the control group. The McNemar’s Chi-square was the p value used 
here. 
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Table VI.3 Statistica report tables of input values for statistical significance 
calculations between the study groups within the outer ear study site. The 
Chi-square with 1 degrees freedom (df=1) was the p value used here. 
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Table VI.4 Statistica report tables of input values for determining statistical 
significance between study groups within the nasopharyngeal study site. The 
Chi-squared with 1 degrees of freedom (df=1) was the p value used here. 
